Cancer associated antibody compositions and methods of use

Abstract

To provide novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof.SOLUTION: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] cross reference This application is a continuation of U.S. Provisional Application No. 62 / 840638, filed April 30, 2019, U.S. Provisional Application No. 62 / 840640, filed April 30, 2019, U.S. Provisional Application No. 62 / 840644, filed April 30, 2019, U.S. Provisional Application No. 62 / 840648, filed April 30, 2019, U.S. Provisional Application No. 62 / 840855, filed April 30, 2019, U.S. Provisional Application No. 62 / 840858, filed April 30, 2019, U.S. Provisional Application No. 62 / 840860 filed April 30, 2019, U.S. Provisional Application No. 62 / 840861 filed April 30, 2019, U.S. Provisional Application No. 62 / 840864 filed April 30, 2019, U.S. Provisional Application No. 62 / 840870 filed April 30, 2019, U.S. Provisional Application No. 62 / 840875 filed April 30, 2019, U.S. Provisional Application No. 62 / 840880 filed April 30, 2019 Application No. 62 / 840893, U.S. Provisional Application No. 62 / 840904 filed April 30, 2019, U.S. Provisional Application No. 62 / 840909 filed April 30, 2019, U.S. Provisional Application No. 62 / 840917 filed April 30, 2019, U.S. Provisional Application No. 62 / 840938 filed April 30, 2019, U.S. Provisional Application No. 62 / 840950 filed April 30, 2019, U.S. Provisional Application No. 62 / 84095 filed April 30, 2019 No. 7, filed April 30, 2019, U.S. Provisional Application No. 62 / 840970, filed April 30, 2019, U.S. Provisional Application No. 62 / 841036, filed April 30, 2019, U.S. Provisional Application No. 62 / 841044, filed April 30, 2019, U.S. Provisional Application No. 62 / 841047, filed April 30, 2019, and U.S. Provisional Application No. 62 / 841049, filed April 30, 2019, each of which is incorporated herein by reference in its entirety.

[0002] Reference to sequence listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on April 28, 2020, is titled 54407_705_601_Sequence_Listing.txt and is 4,053,188 bytes in size. [Background technology]

[0003] While the role of cytotoxic T cells in mediating immune responses against cancer is well established, the role of B cells is less known. In particular, the effects of antibodies identified in cancer patients remain unclear. Some studies suggest that such antibodies may promote tumor progression, while others report that they may stimulate antitumor immunity. Summary of the Invention

[0004] In one aspect, provided herein is an antibody or antigen-binding fragment thereof comprising at least one of variable heavy chain complementarity determining region 1 (CDR-H1), CDR-H2, and CDR-H3, wherein CDR-H1 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 543-813, CDR-H2 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1085-1355, and CDR-H3 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1627-1897.

[0005] In one aspect, provided herein is an antibody or antigen-binding fragment thereof comprising at least one of variable light chain complementarity determining region 1 (CDR-L1), CDR-L2, and CDR-L3, wherein CDR-L1 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 814-1084, CDR-L2 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1356-1626, and CDR-L3 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1898-2168.

[0006] In one aspect, provided herein is an antibody or antigen-binding fragment thereof comprising a variable heavy chain complementarity determining region 1 (CDR-H1), CDR-H2, and CDR-H3, and a variable light chain complementarity determining region 1 (CDR-L1), CDR-L2, and CDR-L3, wherein CDR-H1 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 543-813, CDR-H2 comprises a reshaped polypeptide consensus sequence selected from any one of SEQ ID NOs: 1085-1355, and CDR- H3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOs: 1627 to 1897, CDR-L1 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOs: 814 to 1084, CDR-L2 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOs: 1356 to 1626, and CDR-L3 comprises a reconstructed polypeptide consensus sequence selected from any one of SEQ ID NOs: 1898 to 2168.

[0007] In some embodiments, the antibody comprises an IgG, IgA, or IgM antibody. In some embodiments, IgG comprises IgG1, IgG2, IgG3, IgG4, IgGA1, or IgGA2. In some embodiments, the antibody comprises a chimeric antibody, a humanized antibody, a human antibody, a monoclonal antibody, a deimmunized antibody, a bispecific antibody, a multispecific antibody, a multivalent antibody, or a combination thereof. In some embodiments, the antigen-binding fragment comprises a Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, a diabody, a linear antibody, a single domain antibody (sdAb), a camelid VHH domain, or a multispecific antibody formed from antibody fragments. In some embodiments, the antibody or antigen-binding fragment thereof is recombinant or synthetic. In some embodiments, the antibody or antigen-binding fragment thereof further comprises an enzyme, a substrate, a cofactor, a fluorescent marker, a chemiluminescent marker, a peptide tag, a magnetic particle, a drug, a toxin, or a combination thereof. In some embodiments, the antibody or antigen-binding fragment thereof is cytolytic to tumor or cancer cells. In some embodiments, the antibody or antigen-binding fragment thereof inhibits tumor growth or cancer cell growth.

[0008] In some embodiments, the antibody or antigen-binding fragment thereof is useful in the treatment of cancer. In some embodiments, the antibody or antigen-binding fragment thereof of the above aspects is used to treat bladder cancer (e.g., bladder urothelial carcinoma, squamous cell carcinoma of the bladder, adenocarcinoma of the bladder, or small cell carcinoma of the bladder), brain tumor (glioma, meningioma, pituitary adenoma, vestibular schwannoma, nerve sheath tumor, primitive neuroectodermal tumor (e.g., medulloblastoma), ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, mixed glioma (e.g., oligoastrocytoma), high-grade glioma, or low-grade glioma), breast cancer or breast carcinoma (e.g., invasive ductal carcinoma, ductal carcinoma in situ, invasive lobular carcinoma, lobular carcinoma in situ, inflammatory breast cancer, male breast cancer, phyllodes tumor of the breast, Paget's disease of the nipple, angiosarcoma, or metastatic breast cancer), cervical cancer (cervical squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, ground glass cell carcinoma, villous adenocarcinoma, internal cervical (NOS)-type adenocarcinoma, mucinous adenocarcinoma, minimal deviation adenocarcinoma (mucinous and endometrioid), intestinal / GI-type adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, serous adenocarcinoma, mesonephric adenocarcinoma, adenoid basal cell carcinoma, or adenoid cystic carcinoma), bile duct cancer (e.g., intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, or distal bile duct carcinoma), colon or rectal cancer (e.g., colon adenocarcinoma, rectal adenocarcinoma, gastrointestinal carcinoid tumor, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, melanoma, sarcoma, Turcot syndrome, Peutz-Jeghers syndrome, familial colorectal cancer, or juvenile polyposis coli), esophageal cancer (e.g., squamous cell carcinoma, adenocarcinoma, choriocarcinoma, lymphoma, melanoma, head or neck squamous cell carcinoma (conventional squamous cell carcinoma, verrucous carcinoma, basaloid squamous cell carcinoma, papillary squamous cell carcinoma, spindle cell carcinoma, acantholytic squamous cell carcinoma, adenosquamous carcinoma, ostial carcinoma, nasopharyngeal carcinoma, lymphoepithelial carcinoma, laryngeal or hypopharyngeal carcinoma, nasal cavity or paranasal sinus carcinoma, nasopharyngeal carcinoma, oral cavity and oropharyngeal carcinoma, salivary gland carcinoma, HPV-negative squamous cell carcinoma, or HPV-induced squamous cell carcinoma), kidney cancer (e.g., renal cell carcinoma, renal pelvis carcinoma, Cancer, transitional cell carcinoma, squamous cell carcinoma, juxtaglomerular tumor (nephroma), angiomyolipoma, Bellini duct carcinoma, clear cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial-stromal tumor, clear cell adenocarcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, carcinoid tumor of the renal pelvis, clear cell renal carcinoma of the kidney, papillary renal cell carcinoma of the kidney, sarcomatoid renal cell carcinoma, chromophobe renal carcinoma, medullary renal carcinoma, collecting duct renal cell carcinoma, unclassified renal cell carcinoma, renal oncocytoma, angiomyolipoma, or or clear cell papillary carcinoma), liver cancer (e.g., hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, mucinous cystic tumor, intraductal papillary bile duct tumor, hepatoblastoma, cholangiocytic cystadenocarcinoma, angiosarcoma, hemangioendothelioma, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, yolk sac tumor, carcinoid tumor, lymphoma, or liver metastasis), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, carcinoid tumor, These compounds are useful in the treatment of tumors including bronchial adenocarcinoma, carcinosarcoma, pulmonary blastoma, giant cell or spindle cell carcinoma, or sarcomatoid carcinoma), mesothelioma (e.g., malignant mesothelioma or malignant pleural mesothelioma, cystadenocarcinoma (e.g., ovarian serous cystadenocarcinoma), adenocarcinoma (e.g., pancreatic adenocarcinoma), pheochromocytoma or paraganglioma, prostate adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell carcinoma, thyroid cancer, uterine cancer (e.g., uterine carcinosarcoma or endometrial carcinoma), and uveal melanoma.

[0009] In one aspect, provided herein is an antibody or antigen-binding fragment thereof, comprising a variable heavy chain comprising a reconstructed polypeptide consensus sequence having at least 95% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 1-271, and / or a variable light chain comprising a reconstructed polypeptide consensus sequence having at least 95% sequence identity to an amino acid sequence selected from any one of SEQ ID NOs: 272-542.

[0010] In one aspect, provided herein is a hybridoma producing the antibody or antigen-binding fragment thereof according to any one of the above aspects.

[0011] Provided herein is a fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of the above aspects.

[0012] Provided herein is a chimeric antigen receptor or T cell receptor fusion protein comprising the antigen-binding fragment of any one of the above aspects, a transmembrane domain, and an intracellular signaling domain.

[0013] Provided herein is a T cell receptor fusion protein comprising the antibody or antigen-binding fragment thereof according to any one of the above aspects and a T cell receptor (TCR) subunit. In some embodiments, the antibody or antigen-binding fragment thereof comprises a human or humanized anti-cancer antigen-binding domain. In some embodiments, the TCR subunit comprises at least a portion of the TCR extracellular domain, a transmembrane domain, and a TCR intracellular domain comprising a stimulatory domain from the intracellular signaling domain. In some embodiments, the extracellular, transmembrane, and intracellular signaling domains of the TCR subunit are derived from either CD3 epsilon alone or CD3 gamma alone. In some embodiments, the antibody or antigen-binding fragment thereof and the TCR extracellular domain are connected by a linker sequence. In some embodiments, the linker sequence comprises the sequence (G4S)n, where G is glycine, S is serine, and n=1 to 4.

[0014] An isolated gene encoding a T cell receptor fusion protein according to any of the above embodiments. Recombinant nucleic acid molecules are provided herein.

[0015] Provided herein are vectors comprising the above-described isolated recombinant nucleic acid molecules.

[0016] Provided herein is a host cell comprising the isolated recombinant nucleic acid molecule or the vector. In some embodiments, the host cell is a T cell.

[0017] Provided herein is a T cell expressing the T cell receptor fusion protein of any one of the above aspects. In some embodiments, the T cell receptor fusion protein is functionally integrated with an endogenous T cell receptor. In some embodiments, the T cell is a CD8+ or CD4+ T cell.

[0018] Provided herein is an immunoconjugate comprising an antibody or antigen-binding fragment thereof according to any one of the above aspects and a therapeutic agent.

[0019] Provided herein is a pharmaceutical composition or medicament comprising the antibody or antigen-binding fragment thereof of any one of the above aspects and a pharmaceutically acceptable carrier, excipient, or diluent. In some embodiments, the pharmaceutical composition further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent, radiation therapy, a cytotoxic agent, another antibody, a nutritional supplement such as an NSAID, a corticosteroid, an antioxidant, or a combination thereof. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent. In some embodiments, the pharmaceutical composition of any one of the above aspects is formulated for administration via a subcutaneous, intravenous, intradermal, intraperitoneal, intramuscular, intraventricular, intracranial, intracavitary, or intracerebellar route of administration. In some embodiments, the pharmaceutical composition of any one of the above aspects is in aqueous or lyophilized form. In some embodiments, the pharmaceutical composition of any one of the above aspects is contained within a delivery device selected from the group consisting of a syringe, a blunt-needle syringe, a catheter, and an implantable pump.

[0020] Provided herein is a use of an antibody or antigen-binding fragment thereof according to any one of the above aspects for treating cancer.

[0021] Provided herein is use of an antibody or antigen-binding fragment thereof according to any one of the above aspects, or the immunoconjugate described above, in the manufacture of a medicament. In some embodiments, the medicament is for the treatment of cancer.

[0022] Provided herein are methods for treating a subject suffering from cancer, the methods comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof according to any one of the above aspects. In some embodiments, the antibody or antigen-binding fragment thereof is cytolytic to tumor cells. In some embodiments, the antibody or antigen-binding fragment thereof inhibits tumor growth.

[0023] In some embodiments, the cancer is bladder cancer (e.g., bladder urothelial carcinoma, squamous cell carcinoma of the bladder, adenocarcinoma of the bladder, or small cell carcinoma of the bladder), brain tumor (glioma, meningioma, pituitary adenoma, vestibular schwannoma, nerve sheath tumor, primitive neuroectodermal tumor (e.g., medulloblastoma), ependymoma, astrocytoma, oligodendroglioma, brain stem glioma, optic nerve glioma, mixed glioma (e.g., oligoastrocytoma), high-grade glioma, or low-grade glioma), breast cancer or breast carcinoma (e.g., invasive ductal carcinoma, ductal carcinoma in situ, invasive lobular carcinoma, lobular carcinoma in situ, inflammatory breast cancer, male breast cancer, phyllodes tumor of the breast, Paget's disease of the nipple, angiosarcoma, or metastatic breast cancer), cervical cancer (cervical squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, ground glass cell carcinoma, villous adenocarcinoma, endocrine (NOS) type adenocarcinoma, mucinous liquid adenocarcinoma, minimally skewed adenocarcinoma (mucinous and endometrioid), intestinal / GI-type adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, serous adenocarcinoma, mesonephric adenocarcinoma, adenoid basal cell carcinoma, or adenoid cystic carcinoma), bile duct cancer (e.g., intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, or distal bile duct carcinoma), colon or rectal cancer (e.g., colon adenocarcinoma, rectal adenocarcinoma, gastrointestinal carcinoid tumor, primary colorectal lymphoma, gastrointestinal stromal tumor, leiomyosarcoma, melanoma, sarcoma, Turcot syndrome, Peutz-Jeghers syndrome, familial colorectal cancer, or juvenile polyposis coli), esophageal cancer (e.g., squamous cell carcinoma, glandular carcinoma, cancer of the head or neck (conventional squamous cell carcinoma, warty carcinoma, basaloid squamous cell carcinoma, papillary squamous cell carcinoma, spindle cell carcinoma, acantholytic squamous cell carcinoma, adenosquamous carcinoma, ductal carcinoma, nasopharyngeal carcinoma, lymphoepithelial carcinoma, laryngeal or hypopharyngeal carcinoma, nasal cavity or paranasal sinus carcinoma, nasopharyngeal carcinoma, oral cavity and oropharyngeal carcinoma, salivary gland carcinoma, HPV-negative squamous cell carcinoma, or HPV-induced squamous cell carcinoma), kidney cancer (e.g., renal cell carcinoma, renal pelvis carcinoma, transitional cell carcinoma, squamous cell carcinoma, juxtaglomerular carcinoma (nephroma), angiomyolipoma, Bellini duct carcinoma) cancer, clear cell sarcoma of the kidney, mesoblastic nephroma, Wilms' tumor, mixed epithelial-stromal tumor, clear cell adenocarcinoma, inverted papilloma, renal lymphoma, teratoma, carcinosarcoma, carcinoid tumor of the renal pelvis, clear cell renal carcinoma of the kidney, papillary renal cell carcinoma of the kidney, sarcomatoid renal cell carcinoma, chromophobe renal carcinoma, medullary renal carcinoma, collecting duct renal cell carcinoma, unclassified renal cell carcinoma, oncocytoma of the kidney, angiomyolipoma, or clear cell papillary carcinoma), liver cancer (e.g., hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, mucinous cystic tumor, intraductal papillary bile duct tumor, hepatoblastoma, cholangiocytic cystadenocarcinoma, angiosarcoma, hemangioendothelioma, embryonal sarcoma, adenocarcinoma, fibroblastic ... fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, cholangiocytic cystadenocarcinoma, cholangiocarcinoma, cholangiocytic cystadenocarcinoma, cholangiocarcinoma, cholangiocytic cystadenocarcinoma, cholangiosarcoma, cholangiocytic cystadeno fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, yolk sac tumor, carcinoid tumor, lymphoma, or liver metastasis), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, carcinoid tumor, bronchial adenocarcinoma, carcinosarcoma, pulmonary blastoma, giant cell or spindle cell carcinoma, or sarcomatoid carcinoma), mesothelioma (e.g., malignant mesothelioma or malignant pleural mesothelioma, cystadenocarcinoma (e.g., ovarian serous cystadenocarcinoma), adenocarcinoma (e.g., pancreatic adenocarcinoma), pheochromocytoma or paraganglioma, prostate adenocarcinoma, sarcoma, cutaneous melanoma, gastric adenocarcinoma, testicular germ cell carcinoma,Thyroid cancer, uterine cancer (e.g., uterine carcinosarcoma or endometrial cancer), uveal melanoma.

[0024] In some embodiments, the antibody or antigen-binding fragment thereof is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially. In some embodiments, the antibody or antigen-binding fragment thereof is administered to the subject in combination with a second therapeutic agent. In some embodiments, the second therapeutic agent comprises a cancer chemotherapeutic agent, radiation therapy, a cytotoxic agent, another antibody, a nutritional supplement such as an NSAID, a corticosteroid, an antioxidant, or a combination thereof. In some embodiments, the anti-cancer agent is an anti-cancer antibody or a chemotherapeutic agent. In some embodiments, the second therapeutic agent is administered before, simultaneously with, or after administration of the antibody or antigen-binding fragment.

[0025] Provided herein are isolated nucleic acid molecules comprising at least one of a nucleic acid sequence encoding a CDR-H1 selected from SEQ ID NOs: 2711-2981, a nucleic acid sequence encoding a CDR-H2 selected from SEQ ID NOs: 3253-3523, a nucleic acid sequence encoding a CDR-H3 selected from SEQ ID NOs: 3795-4065, a nucleic acid sequence encoding a CDR-L1 selected from SEQ ID NOs: 2982-3252, a nucleic acid sequence encoding a CDR-L2 selected from 3524-3794, or a nucleic acid sequence encoding a CDR-L3 selected from SEQ ID NOs: 4066-4336.

[0026] In some embodiments, the nucleic acid sequence is selected from any one of SEQ ID NOs: 2169-2439.

[0027] Provided herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a light chain polypeptide of the antibody, wherein the nucleic acid sequence is selected from any one of SEQ ID NOs: 2440-2710. do.

[0028] Provided herein is a vector comprising the isolated nucleic acid molecule according to any one of the above aspects.

[0029] 98. The vector of claim 97, wherein the isolated nucleic acid is operably linked to a regulatory control sequence.

[0030] Provided herein is a host cell comprising the above vector or the isolated nucleic acid molecule according to any one of the above aspects.

[0031] Provided herein are methods for producing antibodies or antigen-binding fragments thereof, the methods comprising: (a) culturing the host cells described above in a medium under conditions that allow expression of the polypeptides encoded by the isolated nucleic acid molecules and assembly of the antibodies or antigen-binding fragments thereof, and purifying the antibodies or antigen-binding fragments thereof from the cultured cells or cell medium.

[0032] Provided herein is a kit comprising a therapeutically effective amount of at least one antibody or antigen-binding fragment thereof according to any one of the above aspects. In some embodiments, the kit further comprises a therapeutically effective amount of a second therapeutic agent. In some embodiments, the second therapeutic agent is an anti-cancer drug, radiation therapy, a cytotoxic agent, an NSAID, a corticosteroid, a nutritional supplement such as an antioxidant, or a combination thereof. In some embodiments, the anti-cancer drug is an anti-cancer antibody or a chemotherapeutic agent. In some embodiments, the antibody or antigen-binding fragment thereof is in lyophilized or aqueous form. In some embodiments, the kit further comprises a reconstitution solution or diluent.

[0033] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to R-spondin 1, transcript variant 2 (RSPO1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 543, a CDR-H2 of SEQ ID NO: 1085, and a CDR-H3 of SEQ ID NO: 1627, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 814, a CDR-L2 of SEQ ID NO: 1356, and a CDR-L3 of SEQ ID NO: 1898. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RSPO1, mouse RSPO1, rat RSPO1, bovine RSPO1, or cynomolgus RSPO1. In some embodiments, the human RSPO1 comprises the sequence of SEQ ID NO:4337.

[0034] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 107-110 for binding to RSPO1, wherein the antibody binds to human RSPO1 or mouse RSPO1.

[0035] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger DHHC type-containing 1, transcript variant 1 (ZDHHC1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 545, a CDR-H2 of SEQ ID NO: 1087, and a CDR-H3 of SEQ ID NO: 1629, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 816, a CDR-L2 of SEQ ID NO: 1358, and a CDR-L3 of SEQ ID NO: 1900. In some embodiments, the variable heavy chain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 3. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 274. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZDHHC1, mouse ZDHHC1, rat ZDHHC1, bovine ZDHHC1, or cynomolgus monkey ZDHHC1. In some embodiments, the human ZDHHC1 comprises the sequence of SEQ ID NO: 4338.

[0036] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 112-115 for binding to ZDHHC1, wherein the antibody binds to human ZDHHC1 or mouse ZDHHC1.

[0037] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to retinoid X receptor alpha, transcript variant 1 (RXRA) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 546, a CDR-H2 of SEQ ID NO: 1088, and a CDR-H3 of SEQ ID NO: 1630, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 817, a CDR-L2 of SEQ ID NO: 1359, and a CDR-L3 of SEQ ID NO: 1901. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RXRA, mouse RXRA, rat RXRA, bovine RXRA, or cynomolgus RXRA. In some embodiments, the human RXRA comprises the sequence of SEQ ID NO: 4339.

[0038] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 117 to 120 for binding to RXRA, wherein the antibody binds to human RXRA or mouse RXRA.

[0039] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to retinoid X receptor gamma, transcript variant 1 (RXRG) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 546, a CDR-H2 of SEQ ID NO: 1088, and a CDR-H3 of SEQ ID NO: 1630, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 817, a CDR-L2 of SEQ ID NO: 1359, and a CDR-L3 of SEQ ID NO: 1901. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RXRG, mouse RXRG, rat RXRG, bovine RXRG, or cynomolgus RXRG. In some embodiments, human RXRG comprises the sequence of SEQ ID NO:4340.

[0040] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 122-125 for binding to RXRG, wherein the antibody binds to human RXRG or mouse RXRG.

[0041] Selectively binds to transmembrane protein 154 (TMEM154) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 547, a CDR-H2 of SEQ ID NO: 1089, and a CDR-H3 of SEQ ID NO: 1631, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 818, a CDR-L2 of SEQ ID NO: 1360, and a CDR-L3 of SEQ ID NO: 1902. Provided herein are antibodies or antigen-binding fragments thereof that bind to human TMEM154. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:5, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:276. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TMEM154, mouse TMEM154, rat TMEM154, bovine TMEM154, or cynomolgus monkey TMEM154. In some embodiments, the human TMEM154 comprises the sequence of SEQ ID NO:4341.

[0042] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 127-130 for binding to TMEM154, wherein the antibody binds to human TMEM154 or murine TMEM154.

[0043] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SNAP-associated protein, transcript variant 1 (SNAPIN) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 548, a CDR-H2 of SEQ ID NO: 1090, and a CDR-H3 of SEQ ID NO: 1632, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 819, a CDR-L2 of SEQ ID NO: 1361, and a CDR-L3 of SEQ ID NO: 1903. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 277. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SNAPIN, mouse SNAPIN, rat SNAPIN, bovine SNAPIN, or cynomolgus SNAPIN. In some embodiments, the human SNAPIN comprises the sequence of SEQ ID NO:4342.

[0044] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 132 to 135 for binding to SNAPIN, wherein the antibody binds to human SNAPIN or mouse SNAPIN.

[0045] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to glycogen phosphorylase L, transcript variant 1 (PYGL), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PYGL, mouse PYGL, rat PYGL, bovine PYGL, or cynomolgus PYGL. In some embodiments, the human PYGL comprises the sequence of SEQ ID NO:4343.

[0046] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 137-140 for binding to PYGL, wherein the antibody binds to human PYGL or murine PYGL.

[0047] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to reticulocalbin 3 (RCN3) or a variant thereof, comprising at least one of a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RCN3, mouse RCN3, rat RCN3, bovine RCN3, or cynomolgus RCN3. In some embodiments, the human RCN3 comprises the sequence of SEQ ID NO: 4344.

[0048] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 142 to 145 for binding to RCN3, wherein the antibody binds to human RCN3 or mouse RCN3.

[0049] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to synaptotagmin 12, transcript variant X4 (SYT12), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 278. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SYT12, mouse SYT12, rat SYT12, bovine SYT12, or cynomolgus SYT12. In some embodiments, the human SYT12 comprises the sequence of SEQ ID NO: 4345.

[0050] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 147 to 150 for binding to SYT12, wherein the antibody binds to human SYT12 or mouse SYT12.

[0051] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nuclear receptor subfamily 2 group f member 6 (Nr2f6) or a variant thereof, comprising at least one of the following:

[0052] a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 550, a CDR-H2 of SEQ ID NO: 1092, and a CDR-H3 of SEQ ID NO: 1634; and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 821, a CDR-L2 of SEQ ID NO: 1363, and a CDR-L3 of SEQ ID NO: 1905. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 279. In some embodiments, the antibody or antigen-binding fragment thereof binds to human Nr2f6, mouse Nr2f6, rat Nr2f6, bovine Nr2f6, or cynomolgus monkey Nr2f6. In some embodiments, the human Nr2f6 comprises the sequence of SEQ ID NO: 4346.

[0053] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 152 to 155 for binding to Nr2f6, wherein the antibody binds to human Nr2f6 or mouse Nr2f6.

[0054] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to protein phosphatase 1 regulatory subunit 13-like, transcript variant 2 (PPP1R13L) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 550, a CDR-H2 of SEQ ID NO: 1092, and a CDR-H3 of SEQ ID NO: 1634, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 821, a CDR-L2 of SEQ ID NO: 1363, and a CDR-L3 of SEQ ID NO: 1905. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 279. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PPP1R13L, mouse PPP1R13L, rat PPP1R13L, bovine PPP1R13L, or cynomolgus monkey PPP1R13L. In some embodiments, the human PPP1R13L comprises the sequence of SEQ ID NO: 4347.

[0055] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 157 to 160 for binding to PPP1R13L, wherein the antibody binds to human PPP1R13L or mouse PPP1R13L.

[0056] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to olfactory receptor family 6 subfamily Q member 1 (gene / pseudogene) (OR6Q1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 552, a CDR-H2 of SEQ ID NO: 1094, and a CDR-H3 of SEQ ID NO: 1636, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 823, a CDR-L2 of SEQ ID NO: 1365, and a CDR-L3 of SEQ ID NO: 1907. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 281. In some embodiments, the antibody or antigen-binding fragment thereof binds to human OR6Q1, mouse OR6Q1, rat OR6Q1, bovine OR6Q1, or cynomolgus OR6Q1. In some embodiments, the human OR6Q1 comprises the sequence of SEQ ID NO: 4348.

[0057] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 162 to 165 for binding to OR6Q1, wherein the antibody binds to human OR6Q1 or mouse OR6Q1.

[0058] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to cancer / testis antigen 1A (CTAG1A) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 553, a CDR-H2 of SEQ ID NO: 1095, and a CDR-H3 of SEQ ID NO: 1637, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 824, a CDR-L2 of SEQ ID NO: 1366, and a CDR-L3 of SEQ ID NO: 1908. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 282. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CTAG1A, mouse CTAG1A, rat CTAG1A, bovine CTAG1A, or cynomolgus CTAG1A. In some embodiments, the human CTAG1A comprises the sequence of SEQ ID NO: 4349.

[0059] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 167-170 for binding to CTAG1A, wherein the antibody binds to human CTAG1A or mouse CTAG1A.

[0060] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to cancer / testis antigen 1A (CTAG1A) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 554, a CDR-H2 of SEQ ID NO: 1096, and a CDR-H3 of SEQ ID NO: 1638, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 825, a CDR-L2 of SEQ ID NO: 1367, and a CDR-L3 of SEQ ID NO: 1909. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 283. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CTAG1A, mouse CTAG1A, rat CTAG1A, bovine CTAG1A, or cynomolgus CTAG1A. In some embodiments, the human CTAG1A comprises the sequence of SEQ ID NO: 4349.

[0061] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 172-175 for binding to CTAG1A, wherein the antibody binds to human CTAG1A or mouse CTAG1A.

[0062] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to 5-hydroxytryptamine receptor 1E (HTR1E) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 555, a CDR-H2 of SEQ ID NO: 1097, and a CDR-H3 of SEQ ID NO: 1639, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 826, a CDR-L2 of SEQ ID NO: 1368, and a CDR-L3 of SEQ ID NO: 1910. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 13, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 284. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HTR1E, mouse HTR1E, rat HTR1E, bovine HTR1E, or cynomolgus monkey HTR1E. In some embodiments, the human HTR1E comprises the sequence of SEQ ID NO: 4350.

[0063] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 177-180 for binding to HTR1E, wherein the antibody binds to human HTR1E or murine HTR1E.

[0064] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microfibril-associated protein 3, transcript variant 3 (MFAP3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 557, a CDR-H2 of SEQ ID NO: 1099, and a CDR-H3 of SEQ ID NO: 1641, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 828, a CDR-L2 of SEQ ID NO: 1370, and a CDR-L3 of SEQ ID NO: 1912. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 286. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MFAP3, mouse MFAP3, rat MFAP3, bovine MFAP3, or cynomolgus MFAP3. In some embodiments, the human MFAP3 comprises the sequence of SEQ ID NO: 4351. .

[0065] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 182 to 185 for binding to MFAP3, wherein the antibody binds to human MFAP3 or mouse MFAP3.

[0066] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 559, a CDR-H2 of SEQ ID NO: 1101, and a CDR-H3 of SEQ ID NO: 1643, and / or

[0067] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hyaluronan binding protein 4 (HABP4) or a variant thereof, comprising at least one variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 830, CDR-L2 of SEQ ID NO: 1372, and CDR-L3 of SEQ ID NO: 1914. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 288. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HABP4, mouse HABP4, rat HABP4, bovine HABP4, or cynomolgus monkey HABP4. In some embodiments, the human HABP4 comprises the sequence of SEQ ID NO: 4352.

[0068] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 187 to 190 for binding to HABP4, wherein the antibody binds to human HABP4 or mouse HABP4.

[0069] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to glucuronidase, beta pseudogene (BC025996.2_frag) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 561, a CDR-H2 of SEQ ID NO: 1103, and a CDR-H3 of SEQ ID NO: 1645, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 832, a CDR-L2 of SEQ ID NO: 1374, and a CDR-L3 of SEQ ID NO: 1916. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 290. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BC025996.2_frag, mouse BC025996.2_frag, rat BC025996.2_frag, bovine BC025996.2_frag, or cynomolgus monkey BC025996.2_frag. In some embodiments, human BC025996.2_frag comprises the sequence of SEQ ID NO: 4353.

[0070] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 192-195 for binding to BC025996.2_frag, wherein the antibody binds to human BC025996.2_frag or murine BC025996.2_frag.

[0071] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to dual specificity phosphatase 12 (DUSP12) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 562, a CDR-H2 of SEQ ID NO: 1104, and a CDR-H3 of SEQ ID NO: 1646, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 833, a CDR-L2 of SEQ ID NO: 1375, and a CDR-L3 of SEQ ID NO: 1917. In some embodiments, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DUSP12, mouse DUSP12, rat DUSP12, bovine DUSP12, or cynomolgus monkey DUSP12. In some embodiments, the human DUSP12 comprises the sequence of SEQ ID NO: 4354.

[0072] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 197-200 for binding to DUSP12, wherein the antibody binds to human DUSP12 or mouse DUSP12.

[0073] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to actinin alpha 1, transcript variant 2 (ACTN1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 562, a CDR-H2 of SEQ ID NO: 1104, and a CDR-H3 of SEQ ID NO: 1646, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 833, a CDR-L2 of SEQ ID NO: 1375, and a CDR-L3 of SEQ ID NO: 1917. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ACTN1, mouse ACTN1, rat ACTN1, bovine ACTN1, or cynomolgus ACTN1. In some embodiments, the human ACTN1 comprises the sequence of SEQ ID NO: 4355.

[0074] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 202 to 205 for binding to ACTN1, wherein the antibody binds to human ACTN1 or mouse ACTN1.

[0075] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger 4 with KRAB and SCAN domains, transcript variant X1 (ZKSCAN4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 564, a CDR-H2 of SEQ ID NO: 1106, and a CDR-H3 of SEQ ID NO: 1648, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 835, a CDR-L2 of SEQ ID NO: 1377, and a CDR-L3 of SEQ ID NO: 1919. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 293. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZKSCAN4, mouse ZKSCAN4, rat ZKSCAN4, bovine ZKSCAN4, or cynomolgus ZKSCAN4. In some embodiments, the human ZKSCAN4 comprises the sequence of SEQ ID NO: 4356.

[0076] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 207-210 for binding to ZKSCAN4, wherein the antibody binds to human ZKSCAN4 or murine ZKSCAN4.

[0077] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 566, a CDR-H2 of SEQ ID NO: 1108, and a CDR-H3 of SEQ ID NO: 1650, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 837, a CDR-L2 of SEQ ID NO: 1379, and a CDR-L3 of SEQ ID NO: 1921; Provided herein are antibodies or antigen-binding fragments thereof that selectively bind to PNMA family member 5, transcript variant 2 (PNMA5) or variants thereof, including those of SEQ ID NO: 1. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 295. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus PNMA5. In some embodiments, the human PNMA5 comprises the sequence of SEQ ID NO: 4357.

[0078] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 212-215 for binding to PNMA5, wherein the antibody binds to human PNMA5 or murine PNMA5.

[0079] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kelch-like family member 40 (KLHL40) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 567, a CDR-H2 of SEQ ID NO: 1109, and a CDR-H3 of SEQ ID NO: 1651, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 838, a CDR-L2 of SEQ ID NO: 1380, and a CDR-L3 of SEQ ID NO: 1922. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KLHL40, mouse KLHL40, rat KLHL40, bovine KLHL40, or cynomolgus KLHL40. In some embodiments, the human KLHL40 comprises the sequence of SEQ ID NO: 4358.

[0080] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 217 to 220 for binding to KLHL40, wherein the antibody binds to human KLHL40 or mouse KLHL40.

[0081] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to membrane palmitoylated protein 2, transcript variant 3 (MPP2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 567, a CDR-H2 of SEQ ID NO: 1109, and a CDR-H3 of SEQ ID NO: 1651, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 838, a CDR-L2 of SEQ ID NO: 1380, and a CDR-L3 of SEQ ID NO: 1922. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MPP2, mouse MPP2, rat MPP2, bovine MPP2, or cynomolgus MPP2. In some embodiments, the human MPP2 comprises the sequence of SEQ ID NO: 4359.

[0082] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 222-225 for binding to MPP2, wherein the antibody binds to human MPP2 or mouse MPP2.

[0083] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 568, a CDR-H2 of SEQ ID NO: 1110, and a CDR-H3 of SEQ ID NO: 1652, and / or a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 839, a CDR- Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to butyrophilin subfamily 1 member A1 (BTN1A1) or a variant thereof, comprising at least one variable heavy chain region comprising CDR-L2, and CDR-L3 of SEQ ID NO: 1923. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 297. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BTN1A1, mouse BTN1A1, rat BTN1A1, bovine BTN1A1, or cynomolgus monkey BTN1A1. In some embodiments, the human BTN1A1 comprises the sequence of SEQ ID NO: 4360.

[0084] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 227-230 for binding to BTN1A1, wherein the antibody binds to human BTN1A1 or murine BTN1A1.

[0085] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to peroxisome biogenesis factor 11 gamma, transcript variant 1 (PEX11G) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 569, a CDR-H2 of SEQ ID NO: 1111, and a CDR-H3 of SEQ ID NO: 1653, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 840, a CDR-L2 of SEQ ID NO: 1382, and a CDR-L3 of SEQ ID NO: 1924. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 27, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 298. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PEX11G, mouse PEX11G, rat PEX11G, bovine PEX11G, or cynomolgus PEX11G. In some embodiments, the human PEX11G comprises the sequence of SEQ ID NO: 4361.

[0086] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 232 to 235 for binding to PEX11G, wherein the antibody binds to human PEX11G or mouse PEX11G.

[0087] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 8 (ZNF8) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF8, mouse ZNF8, rat ZNF8, bovine ZNF8, or cynomolgus ZNF8. In some embodiments, human ZNF8 comprises the sequence of SEQ ID NO:4362.

[0088] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 237-240 for binding to ZNF8, wherein the antibody binds to human ZNF8 or mouse ZNF8.

[0089] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SATB homeobox 2, transcript variant 2 (SATB2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SATB2, mouse SATB2, rat SATB2, bovine SATB2, or cynomolgus SATB2. In some embodiments, the human SATB2 comprises the sequence of SEQ ID NO: 4363.

[0090] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 242-245 for binding to SATB2, wherein the antibody binds to human SATB2 or murine SATB2.

[0091] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ganglioside-induced differentiation-associated protein 1, transcript variant 2 (GDAP1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 572, a CDR-H2 of SEQ ID NO: 1114, and a CDR-H3 of SEQ ID NO: 1656, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 843, a CDR-L2 of SEQ ID NO: 1385, and a CDR-L3 of SEQ ID NO: 1927. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 30, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GDAP1, mouse GDAP1, rat GDAP1, bovine GDAP1, or cynomolgus GDAP1. In some embodiments, the human GDAP1 comprises the sequence of SEQ ID NO: 4364.

[0092] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 247-250 for binding to GDAP1, wherein the antibody binds to human GDAP1 or murine GDAP1.

[0093] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to catenin alpha-like 1, transcript variant 1 (CTNNAL1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 578, a CDR-H2 of SEQ ID NO: 1120, and a CDR-H3 of SEQ ID NO: 1662, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 849, a CDR-L2 of SEQ ID NO: 1391, and a CDR-L3 of SEQ ID NO: 1933. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 307. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CTNNAL1, mouse CTNNAL1, rat CTNNAL1, bovine CTNNAL1, or cynomolgus CTNNAL1. In some embodiments, the human CTNNAL1 comprises the sequence of SEQ ID NO: 4365.

[0094] The antibody or antibody according to any one of claims 252 to 255, which binds to CTNNAL1 Provided herein are antibodies that compete with the antigen-binding fragment or antigen-binding fragment of human CTNNAL1 or mouse CTNNAL1.

[0095] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to FA complementarity group G (FANCG) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 579, a CDR-H2 of SEQ ID NO: 1121, and a CDR-H3 of SEQ ID NO: 1663, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 850, a CDR-L2 of SEQ ID NO: 1392, and a CDR-L3 of SEQ ID NO: 1934. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 37, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 308. In some embodiments, the antibody or antigen-binding fragment thereof binds to human FANCG, mouse FANCG, rat FANCG, bovine FANCG, or cynomolgus FANCG. In some embodiments, the human FANCG comprises the sequence of SEQ ID NO:4366.

[0096] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 257-260 for binding to FANCG, wherein the antibody binds to human FANCG or murine FANCG.

[0097] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD-box helicase 18 (DDX18) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX18, mouse DDX18, rat DDX18, bovine DDX18, or cynomolgus DDX18. In some embodiments, the human DDX18 comprises the sequence of SEQ ID NO: 4367.

[0098] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 262-265 for binding to DDX18, wherein the antibody binds to human DDX18 or mouse DDX18.

[0099] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to syntaxin 1A, transcript variant 1 (STX1A) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds to human STX1A, mouse STX1A, rat STX1A, bovine STX1A, or cynomolgus STX1A. In some embodiments, the human STX1A comprises the sequence of SEQ ID NO: 4368.

[0100] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 267-270 for binding to STX1A, wherein the antibody binds to human STX1A or mouse STX1A.

[0101] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to geminin DNA replication inhibitor, transcript variant 1 (GMNN) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 311. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GMNN, mouse GMNN, rat GMNN, bovine GMNN, or cynomolgus GMNN. In some embodiments, the human GMNN comprises the sequence of SEQ ID NO: 4369.

[0102] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 272-275 for binding to GMNN, wherein the antibody binds to human GMNN or mouse GMNN.

[0103] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquilin 1, transcript variant 2 (UBQLN1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 585, a CDR-H2 of SEQ ID NO: 1127, and a CDR-H3 of SEQ ID NO: 1669, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 856, a CDR-L2 of SEQ ID NO: 1398, and a CDR-L3 of SEQ ID NO: 1940. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 43, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 314. In some embodiments, the antibody or antigen-binding fragment thereof binds to human UBQLN1, mouse UBQLN1, rat UBQLN1, bovine UBQLN1, or cynomolgus monkey UBQLN1. In some embodiments, the human UBQLN1 comprises the sequence of SEQ ID NO: 4370.

[0104] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 277-280 for binding to UBQLN1, wherein the antibody binds to human UBQLN1 or mouse UBQLN1.

[0105] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to carnosine dipeptidase 2, transcript variant 1 (CNDP2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 585, a CDR-H2 of SEQ ID NO: 1127, and a CDR-H3 of SEQ ID NO: 1669, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 856, a CDR-L2 of SEQ ID NO: 1398, and a CDR-L3 of SEQ ID NO: 1940. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 43, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 314. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CNDP2, mouse CNDP2, rat CNDP2, bovine CNDP2, or cynomolgus CNDP2. In some embodiments, the human CNDP2 comprises the sequence of SEQ ID NO: 4371.

[0106] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 282-285 for binding to CNDP2, wherein the antibody binds to human CNDP2 or mouse CNDP2.

[0107] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to X-linked inhibitor of apoptosis, transcript variant 2 (XIAP) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 587, a CDR-H2 of SEQ ID NO: 1129, and a CDR-H3 of SEQ ID NO: 1671, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 858, a CDR-L2 of SEQ ID NO: 1400, and a CDR-L3 of SEQ ID NO: 1942. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 45, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 316. In some embodiments, the antibody or antigen-binding fragment thereof binds to human XIAP, mouse XIAP, rat XIAP, bovine XIAP, or cynomolgus XIAP. In some embodiments, the human XIAP comprises the sequence of SEQ ID NO:4372.

[0108] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 287-290 for binding to XIAP, wherein the antibody binds to human XIAP or mouse XIAP.

[0109] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hyaluronan binding protein 4 (HABP4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 587, a CDR-H2 of SEQ ID NO: 1129, and a CDR-H3 of SEQ ID NO: 1671, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 858, a CDR-L2 of SEQ ID NO: 1400, and a CDR-L3 of SEQ ID NO: 1942. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 45, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 316. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HABP4, mouse HABP4, rat HABP4, bovine HABP4, or cynomolgus HABP4. In some embodiments, the human HABP4 comprises the sequence of SEQ ID NO: 4352.

[0110] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 292 to 295 for binding to HABP4, wherein the antibody binds to human HABP4 or mouse HABP4.

[0111] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosomal-associated transport regulator 1, transcript variant 2 (SDCCAG3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 589, a CDR-H2 of SEQ ID NO: 1131, and a CDR-H3 of SEQ ID NO: 1673, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 860, a CDR-L2 of SEQ ID NO: 1402, and a CDR-L3 of SEQ ID NO: 1944. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 47, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 318. In some embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3, and cynomolgus monkey SDCCAG3. In some embodiments, the human SDCCAG3 comprises the sequence of SEQ ID NO: 4373.

[0112] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 297-300 for binding to SDCCAG3, wherein the antibody binds to human SDCCAG3 or mouse SDCCAG3.

[0113] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to charged multivesicular body protein 4B (CHMP4B) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 589, a CDR-H2 of SEQ ID NO: 1131, and a CDR-H3 of SEQ ID NO: 1673, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 860, a CDR-L2 of SEQ ID NO: 1402, and a CDR-L3 of SEQ ID NO: 1944. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 47, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 318. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CHMP4B, mouse CHMP4B, rat CHMP4B, bovine CHMP4B, or cynomolgus CHMP4B. In some embodiments, the human CHMP4B comprises the sequence of SEQ ID NO: 4374.

[0114] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 302 to 305 for binding to CHMP4B, wherein the antibody binds to human CHMP4B or mouse CHMP4B.

[0115] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to glycogenin 2, transcript variant 2 (GYG2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 590, a CDR-H2 of SEQ ID NO: 1132, and a CDR-H3 of SEQ ID NO: 1674, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 861, a CDR-L2 of SEQ ID NO: 1403, and a CDR-L3 of SEQ ID NO: 1945. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 48, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GYG2, mouse GYG2, rat GYG2, bovine GYG2, or cynomolgus GYG2. In some embodiments, the human GYG2 comprises the sequence of SEQ ID NO: 4375.

[0116] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 307 to 310 for binding to GYG2, wherein the antibody binds to human GYG2 or mouse GYG2.

[0117] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Egf-like and emi domain-containing 1, pseudogene (EGFEM1P) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 591, a CDR-H2 of SEQ ID NO: 1133, and a CDR-H3 of SEQ ID NO: 1675, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 862, a CDR-L2 of SEQ ID NO: 1404, and a CDR-L3 of SEQ ID NO: 1946. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 49, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 320. In some embodiments, the antibody or antigen-binding fragment thereof binds to human EGFEM1P, mouse EGFEM1P, rat EGFEM1P, bovine EGFEM1P, or cynomolgus EGFEM1P. In some embodiments, the human EGFEM1P comprises the sequence of SEQ ID NO: 4376.

[0118] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 312 to 315 for binding to EGFEM1P, wherein the antibody binds to human EGFEM1P or mouse EGFEM1P.

[0119] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to actinin alpha 4, transcript variant 1 (ACTN4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 593, a CDR-H2 of SEQ ID NO: 1135, and a CDR-H3 of SEQ ID NO: 1677, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 864, a CDR-L2 of SEQ ID NO: 1406, and a CDR-L3 of SEQ ID NO: 1948. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 51, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 322. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ACTN4, mouse ACTN4, rat ACTN4, bovine ACTN4, or cynomolgus ACTN4. In some embodiments, the human ACTN4 comprises the sequence of SEQ ID NO: 4377.

[0120] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 317-320 for binding to ACTN4, wherein the antibody binds to human ACTN4 or mouse ACTN4.

[0121] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PNMA family member 5, transcript variant 2 (PNMA5) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus PNMA5. In some embodiments, the human PNMA5 comprises the sequence of SEQ ID NO:4357.

[0122] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 322-325 for binding to PNMA5, wherein the antibody binds to human PNMA5 or murine PNMA5.

[0123] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C delta 1, transcript variant 2 (PLCD1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 52. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PLCD1, mouse PLCD1, rat PLCD1, bovine PLCD1, or cynomolgus monkey PLCD1. In some embodiments, the human PLCD1 comprises the sequence of SEQ ID NO: 4378.

[0124] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 327-330 for binding to PLCD1, wherein the antibody binds to human PLCD1 or mouse PLCD1.

[0125] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 326, transcript variant 1 (ZNF326), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 594, a CDR-H2 of SEQ ID NO: 1136, and a CDR-H3 of SEQ ID NO: 1678, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 865, a CDR-L2 of SEQ ID NO: 1407, and a CDR-L3 of SEQ ID NO: 1949. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 52, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 323. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF326, mouse ZNF326, rat ZNF326, bovine ZNF326, or cynomolgus monkey ZNF326. In some embodiments, the human ZNF326 comprises the sequence of SEQ ID NO: 4379.

[0126] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 332-335 for binding to ZNF326, wherein the antibody binds to human ZNF326 or murine ZNF326.

[0127] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to -(LN608403.1_frag) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, a CDR-L2 of SEQ ID NO: 1413, and a CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds to human LN608403.1_frag, mouse LN608403.1_frag, rat LN608403.1_frag, bovine LN608403.1_frag, or cynomolgus monkey LN608403.1_frag. In some embodiments, human LN608403.1_frag comprises the sequence of SEQ ID NO: 4380.

[0128] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 337-340 for binding to LN608403.1_frag, wherein the antibody binds to human LN608403.1_frag or murine LN608403.1_frag.

[0129] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684, and / or Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to the JPX transcript, XIST activator (JPX_frag), or a variant thereof, comprising at least one variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, CDR-L2 of SEQ ID NO: 1413, and CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds to human JPX_frag, mouse JPX_frag, rat JPX_frag, bovine JPX_frag, or cynomolgus JPX_frag. In some embodiments, the human JPX_frag comprises the sequence of SEQ ID NO: 4381.

[0130] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 342 to 345 for binding to JPX_frag, wherein the antibody binds to human JPX_frag or mouse JPX_frag.

[0131] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to odorant binding protein 2A, transcript variant alpha (OBP2A) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 600, a CDR-H2 of SEQ ID NO: 1142, and a CDR-H3 of SEQ ID NO: 1684, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 871, a CDR-L2 of SEQ ID NO: 1413, and a CDR-L3 of SEQ ID NO: 1955. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 58, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 329. In some embodiments, the antibody or antigen-binding fragment thereof binds to human OBP2A, mouse OBP2A, rat OBP2A, bovine OBP2A, or cynomolgus OBP2A. In some embodiments, the human OBP2A comprises the sequence of SEQ ID NO: 4382.

[0132] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 347-350 for binding to OBP2A, wherein the antibody binds to human OBP2A or murine OBP2A.

[0133] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to myelin transcription factor 1-like, transcript variant 2 (MYT1L) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 604, a CDR-H2 of SEQ ID NO: 1146, and a CDR-H3 of SEQ ID NO: 1688, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 875, a CDR-L2 of SEQ ID NO: 1417, and a CDR-L3 of SEQ ID NO: 1959. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 62, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MYT1L, mouse MYT1L, rat MYT1L, bovine MYT1L, or cynomolgus MYT1L. In some embodiments, the human MYT1L comprises the sequence of SEQ ID NO: 4383.

[0134] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 352-355 for binding to MYT1L, wherein the antibody binds to human MYT1L or mouse MYT1L.

[0135] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to heat shock protein family E (Hsp10) member 1 (HSPE1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 604, a CDR-H2 of SEQ ID NO: 1146, and a CDR-H3 of SEQ ID NO: 1688, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 875, a CDR-L2 of SEQ ID NO: 1417, and a CDR-L3 of SEQ ID NO: 1959. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 62, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HSPE1, mouse HSPE1, rat HSPE1, bovine HSPE1, or cynomolgus HSPE1. In some embodiments, the human HSPE1 comprises the sequence of SEQ ID NO: 4384.

[0136] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 357-360 for binding to HSPE1, wherein the antibody binds to human HSPE1 or mouse HSPE1.

[0137] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kelch-like ECH-associated protein 1, transcript variant 1 (KEAP1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 607, a CDR-H2 of SEQ ID NO: 1149, and a CDR-H3 of SEQ ID NO: 1691, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 878, a CDR-L2 of SEQ ID NO: 1420, and a CDR-L3 of SEQ ID NO: 1962. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 65, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 336. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus KEAP1. In some embodiments, the human KEAP1 comprises the sequence of SEQ ID NO: 4385.

[0138] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 362-365 for binding to KEAP1, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0139] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nucleosome assembly protein 1-like 1, transcript variant 1 (NAP1L1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 614, a CDR-H2 of SEQ ID NO: 1156, and a CDR-H3 of SEQ ID NO: 1698, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 885, a CDR-L2 of SEQ ID NO: 1427, and a CDR-L3 of SEQ ID NO: 1969. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 72, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 343. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NAP1L1, mouse NAP1L1, rat NAP1L1, bovine NAP1L1, or cynomolgus monkey NAP1L1. In some embodiments, the human NAP1L1 comprises the sequence of SEQ ID NO: 4386.

[0140] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 367-370 for binding to NAP1L1, wherein the antibody binds to human NAP1L1 or murine NAP1L1.

[0141] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to nudE neurodevelopmental protein 1, transcript variant 1 (NDE1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 615, a CDR-H2 of SEQ ID NO: 1157, and a CDR-H3 of SEQ ID NO: 1699, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 886, a CDR-L2 of SEQ ID NO: 1428, and a CDR-L3 of SEQ ID NO: 1970. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 73, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 344. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NDE1, mouse NDE1, rat NDE1, bovine NDE1, or cynomolgus monkey NDE1. In some embodiments, the human NDE1 comprises the sequence of SEQ ID NO: 4387.

[0142] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 372-375 for binding to NDE1, wherein the antibody binds to human NDE1 or mouse NDE1.

[0143] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to TruB pseudouridine synthase family member 1 (TRUB1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TRUB1, mouse TRUB1, rat TRUB1, bovine TRUB1, or cynomolgus TRUB1. In some embodiments, the human TRUB1 comprises the sequence of SEQ ID NO: 4388.

[0144] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 377-380 for binding to TRUB1, wherein the antibody binds to human TRUB1 or mouse TRUB1.

[0145] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to inosine monophosphate dehydrogenase 2 (IMPDH2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds to human IMPDH2, mouse IMPDH2, rat IMPDH2, bovine IMPDH2, or cynomolgus monkey IMPDH2. In some embodiments, the human IMPDH2 comprises the sequence of SEQ ID NO: 4389.

[0146] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 382-385 for binding to IMPDH2, wherein the antibody binds to human IMPDH2 or murine IMPDH2.

[0147] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipid scramblase 4, transcript variant X4 (PLSCR4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 549, a CDR-H2 of SEQ ID NO: 1091, and a CDR-H3 of SEQ ID NO: 1633, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 820, a CDR-L2 of SEQ ID NO: 1362, and a CDR-L3 of SEQ ID NO: 1904. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PLSCR4, mouse PLSCR4, rat PLSCR4, bovine PLSCR4, or cynomolgus PLSCR4. In some embodiments, the human PLSCR4 comprises the sequence of SEQ ID NO: 4390.

[0148] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 387-390 for binding to PLSCR4, wherein the antibody binds to human PLSCR4 or mouse PLSCR4.

[0149] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 617, a CDR-H2 of SEQ ID NO: 1159, and a CDR-H3 of SEQ ID NO: 1701; and / or

[0150] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to influenza virus NS1A binding protein (IVNS1ABP) or a variant thereof, comprising at least one variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 888, CDR-L2 of SEQ ID NO: 1430, and CDR-L3 of SEQ ID NO: 1972. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 75, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 346. In some embodiments, the antibody or antigen-binding fragment thereof binds to human IVNS1ABP, mouse IVNS1ABP, rat IVNS1ABP, bovine IVNS1ABP, or cynomolgus monkey IVNS1ABP. In some embodiments, the human IVNS1ABP comprises the sequence of SEQ ID NO: 4391.

[0151] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 392-395 for binding to IVNS1ABP, wherein the antibody binds to human IVNS1ABP or murine IVNS1ABP.

[0152] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to disheveled segment polarity protein 3 (DVL3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 618, a CDR-H2 of SEQ ID NO: 1160, and a CDR-H3 of SEQ ID NO: 1702, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 889, a CDR-L2 of SEQ ID NO: 1431, and a CDR-L3 of SEQ ID NO: 1973. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 76, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DVL3, mouse DVL3, rat DVL3, bovine DVL3, or cynomolgus DVL3. In some embodiments, the human DVL3 comprises the sequence of SEQ ID NO: 4392.

[0153] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 397-400 for binding to DVL3, wherein the antibody binds to human DVL3 or mouse DVL3.

[0154] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 260 (ZNF260) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 618, a CDR-H2 of SEQ ID NO: 1160, and a CDR-H3 of SEQ ID NO: 1702, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 889, a CDR-L2 of SEQ ID NO: 1431, and a CDR-L3 of SEQ ID NO: 1973. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 76, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF260, mouse ZNF260, rat ZNF260, bovine ZNF260, or cynomolgus ZNF260. In some embodiments, the human ZNF260 comprises the sequence of SEQ ID NO: 4393.

[0155] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 402-405 for binding to ZNF260, wherein the antibody binds to human ZNF260 or murine ZNF260.

[0156] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to sorting nexin 33, transcript variant 1 (SNX33), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 619, a CDR-H2 of SEQ ID NO: 1161, and a CDR-H3 of SEQ ID NO: 1703, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 890, a CDR-L2 of SEQ ID NO: 1432, and a CDR-L3 of SEQ ID NO: 1974. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 77, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 348. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SNX33, mouse SNX33, rat SNX33, bovine SNX33, or cynomolgus monkey SNX33. In some embodiments, the human SNX33 comprises the sequence of SEQ ID NO: 4394.

[0157] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 407 to 410 for binding to SNX33, wherein the antibody binds to human SNX33 or mouse SNX33.

[0158] at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 620, a CDR-H2 of SEQ ID NO: 1162, and a CDR-H3 of SEQ ID NO: 1704, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 891, a CDR-L2 of SEQ ID NO: 1433, and a CDR-L3 of SEQ ID NO: 1975; Provided herein are antibodies or antigen-binding fragments thereof that selectively bind to Jupiter microtubule-associated homolog 2 (HN1L) or variants thereof, including those of SEQ ID NO: 11444, SEQ ID NO: 11452, SEQ ID NO: 11460, SEQ ID NO: 11470, SEQ ID NO: 11480, SEQ ID NO: 11490, SEQ ID NO: 11491, SEQ ID NO: 11492, SEQ ID NO: 11493, SEQ ID NO: 11494, SEQ ID NO: 11495, SEQ ID NO: 11496, SEQ ID NO: 11497, SEQ ID NO: 11498, SEQ ID NO: 1149 ...

[0159] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 412 to 415 for binding to HN1L, wherein the antibody binds to human HN1L or mouse HN1L.

[0160] Provided herein are antibodies or antigen-binding fragments thereof that selectively bind to thioesterase superfamily member 6, transcript variant 1 (THEM6) or variants thereof, including at least one of the following:

[0161] a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 620, a CDR-H2 of SEQ ID NO: 1162, and a CDR-H3 of SEQ ID NO: 1704, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 891, a CDR-L2 of SEQ ID NO: 1433, and a CDR-L3 of SEQ ID NO: 1975. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 78, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 349. In some embodiments, the antibody or antigen-binding fragment thereof binds to human THEM6, mouse THEM6, rat THEM6, bovine THEM6, or cynomolgus THEM6. In some embodiments, the human THEM6 comprises the sequence of SEQ ID NO: 4396.

[0162] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 417-420 for binding to THEM6, wherein the antibody binds to human THEM6 or murine THEM6.

[0163] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to KH RNA-binding domain-containing, signaling-related 2, transcription variant 2 (KHDRBS2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 621, a CDR-H2 of SEQ ID NO: 1163, and a CDR-H3 of SEQ ID NO: 1705, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 892, a CDR-L2 of SEQ ID NO: 1434, and a CDR-L3 of SEQ ID NO: 1976. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 79, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 350. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KHDRBS2, mouse KHDRBS2, rat KHDRBS2, bovine KHDRBS2, or cynomolgus KHDRBS2. In some embodiments, the human KHDRBS2 comprises the sequence of SEQ ID NO: 4397.

[0164] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 422-425 for binding to KHDRBS2, wherein the antibody binds to human KHDRBS2 or mouse KHDRBS2.

[0165] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to complement C1q-like 3 (C1QL3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 622, a CDR-H2 of SEQ ID NO: 1164, and a CDR-H3 of SEQ ID NO: 1706, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 893, a CDR-L2 of SEQ ID NO: 1435, and a CDR-L3 of SEQ ID NO: 1977. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 80, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 351. In some embodiments, the antibody or antigen-binding fragment thereof binds to human C1QL3, mouse C1QL3, rat C1QL3, bovine C1QL3, or cynomolgus monkey C1QL3. In some embodiments, the human C1QL3 comprises the sequence of SEQ ID NO: 4398.

[0166] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 427-430 for binding to C1QL3, wherein the antibody binds to human C1QL3 or murine C1QL3.

[0167] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to protein phosphatase 1 regulator subunit 27 (PPP1R27) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 623, a CDR-H2 of SEQ ID NO: 1165, and a CDR-H3 of SEQ ID NO: 1707, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 894, a CDR-L2 of SEQ ID NO: 1436, and a CDR-L3 of SEQ ID NO: 1978. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 81, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PPP1R27, mouse PPP1R27, rat PPP1R27, bovine PPP1R27, or cynomolgus monkey PPP1R27. In some embodiments, the human PPP1R27 comprises the sequence of SEQ ID NO: 4399.

[0168] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 432-435 for binding to PPP1R27, wherein the antibody binds to human PPP1R27 or murine PPP1R27.

[0169] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to deoxyribonuclease 1-like 2, transcript variant 1 (DNASE1L2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 624, a CDR-H2 of SEQ ID NO: 1166, and a CDR-H3 of SEQ ID NO: 1708, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 895, a CDR-L2 of SEQ ID NO: 1437, and a CDR-L3 of SEQ ID NO: 1979. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 82, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 353. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DNASE1L2, mouse DNASE1L2, rat DNASE1L2, bovine DNASE1L2, or cynomolgus monkey DNASE1L2. In some embodiments, the human DNASE1L2 comprises the sequence of SEQ ID NO: 4400.

[0170] The antibody according to any one of claims 437 to 440 for binding to DNASE1L2. Alternatively, provided herein are antibodies that compete with antigen-binding fragments, which antibodies bind to human DNASE1L2 or mouse DNASE1L2.

[0171] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to extended synaptotagmin 2 (ESYT2_frag) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 625, a CDR-H2 of SEQ ID NO: 1167, and a CDR-H3 of SEQ ID NO: 1709, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 896, a CDR-L2 of SEQ ID NO: 1438, and a CDR-L3 of SEQ ID NO: 1980. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 83, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ESYT2_frag, mouse ESYT2_frag, rat ESYT2_frag, bovine ESYT2_frag, or cynomolgus monkey ESYT2_frag. In some embodiments, the human ESYT2_frag comprises the sequence of SEQ ID NO: 4401.

[0172] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 442 to 445 for binding to ESYT2_frag, wherein the antibody binds to human ESYT2_frag or mouse ESYT2_frag.

[0173] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to CC motif chemokine ligand 18 (CCL18) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 626, a CDR-H2 of SEQ ID NO: 1168, and a CDR-H3 of SEQ ID NO: 1710, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 897, a CDR-L2 of SEQ ID NO: 1439, and a CDR-L3 of SEQ ID NO: 1981. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 84, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 355. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CCL18, mouse CCL18, rat CCL18, bovine CCL18, or cynomolgus CCL18. In some embodiments, the human CCL18 comprises the sequence of SEQ ID NO: 4402.

[0174] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 447-450 for binding to CCL18, wherein the antibody binds to human CCL18 or murine CCL18.

[0175] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to homeobox and leucine zipper encoded (HOMEZ) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 627, a CDR-H2 of SEQ ID NO: 1169, and a CDR-H3 of SEQ ID NO: 1711, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 898, a CDR-L2 of SEQ ID NO: 1440, and a CDR-L3 of SEQ ID NO: 1982. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 85, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HOMEZ, mouse HOMEZ, rat HOMEZ, bovine HOMEZ, or cynomolgus HOMEZ. In some embodiments, human HOMEZ comprises the sequence of SEQ ID NO: 4403.

[0176] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 452-455 for binding to HOMEZ, wherein the antibody binds to human HOMEZ or mouse HOMEZ.

[0177] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to BAR / IMD domain-containing adaptor protein 2, transcript variant 3 (BAIAP2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 627, a CDR-H2 of SEQ ID NO: 1169, and a CDR-H3 of SEQ ID NO: 1711, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 898, a CDR-L2 of SEQ ID NO: 1440, and a CDR-L3 of SEQ ID NO: 1982. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 85, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 356. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BAIAP2, mouse BAIAP2, rat BAIAP2, bovine BAIAP2, or cynomolgus BAIAP2. In some embodiments, the human BAIAP2 comprises the sequence of SEQ ID NO: 4404.

[0178] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 457-460 for binding to BAIAP2, wherein the antibody binds to human BAIAP2 or mouse BAIAP2.

[0179] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kelch-like ECH-associated protein 1, transcript variant 1 (KEAP1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 628, a CDR-H2 of SEQ ID NO: 1170, and a CDR-H3 of SEQ ID NO: 17121, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 899, a CDR-L2 of SEQ ID NO: 1441, and a CDR-L3 of SEQ ID NO: 1983. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 86, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 357. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus KEAP1. In some embodiments, the human KEAP1 comprises the sequence of SEQ ID NO: 4385.

[0180] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 462-465 for binding to KEAP1, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0181] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RUN and FYVE domain-containing 3, transcript variant 2 (RUFY3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 629, a CDR-H2 of SEQ ID NO: 1171, and a CDR-H3 of SEQ ID NO: 1713, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 900, a CDR-L2 of SEQ ID NO: 1442, and a CDR-L3 of SEQ ID NO: 1984. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 87, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 358. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RUFY3, mouse RUFY3, rat RUFY3, bovine RUFY3, or cynomolgus monkey RUFY3. In some embodiments, the human RUFY3 comprises the sequence of SEQ ID NO: 4405.

[0182] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 467-470 for binding to RUFY3, wherein the antibody binds to human RUFY3 or mouse RUFY3.

[0183] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to LIM homeobox 5 (LHX5) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 630, a CDR-H2 of SEQ ID NO: 1172, and a CDR-H3 of SEQ ID NO: 1714, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 901, a CDR-L2 of SEQ ID NO: 1443, and a CDR-L3 of SEQ ID NO: 1985. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 88, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody or antigen-binding fragment thereof binds to human LHX5, mouse LHX5, rat LHX5, bovine LHX5, or cynomolgus monkey LHX5. In some embodiments, the human LHX5 comprises the sequence of SEQ ID NO: 4406.

[0184] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 472 to 475 for binding to LHX5, wherein the antibody binds to human LHX5 or mouse LHX5.

[0185] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to growth factor receptor-bound protein 2, transcript variant 1 (GRB2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 630, a CDR-H2 of SEQ ID NO: 1172, and a CDR-H3 of SEQ ID NO: 1714, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 901, a CDR-L2 of SEQ ID NO: 1443, and a CDR-L3 of SEQ ID NO: 1985. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 88, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GRB2, mouse GRB2, rat GRB2, bovine GRB2, or cynomolgus GRB2. In some embodiments, the human GRB2 comprises the sequence of SEQ ID NO:4407.

[0186] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 477-480 for binding to GRB2, wherein the antibody binds to human GRB2 or murine GRB2.

[0187] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to tyrosine hydroxylase (TH) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 631, a CDR-H2 of SEQ ID NO: 1173, and a CDR-H3 of SEQ ID NO: 1715, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 902, a CDR-L2 of SEQ ID NO: 1444, and a CDR-L3 of SEQ ID NO: 1986. In some embodiments, the variable heavy chain is a polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 89. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 360. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TH, mouse TH, rat TH, bovine TH, or cynomolgus TH. In some embodiments, the human TH comprises the sequence of SEQ ID NO: 4408.

[0188] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 482-485 for binding to TH, wherein the antibody binds to human TH or murine TH.

[0189] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to leucine-rich repeat-containing 28, transcript variant 1 (LRRC28) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 633, a CDR-H2 of SEQ ID NO: 1175, and a CDR-H3 of SEQ ID NO: 1717, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 904, a CDR-L2 of SEQ ID NO: 1446, and a CDR-L3 of SEQ ID NO: 1988. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 91, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 362. In some embodiments, the antibody or antigen-binding fragment thereof binds to human LRRC28, mouse LRRC28, rat LRRC28, bovine LRRC28, or cynomolgus monkey LRRC28. In some embodiments, the human LRRC28 comprises the sequence of SEQ ID NO: 4409.

[0190] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 487 to 490 for binding to LRRC28, wherein the antibody binds to human LRRC28 or mouse LRRC28.

[0191] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to spermatogenesis-associated 33, transcript variant 2 (SPATA33) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 635, a CDR-H2 of SEQ ID NO: 1177, and a CDR-H3 of SEQ ID NO: 1719, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 906, a CDR-L2 of SEQ ID NO: 1448, and a CDR-L3 of SEQ ID NO: 1990. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 93, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 364. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SPATA33, mouse SPATA33, rat SPATA33, bovine SPATA33, or cynomolgus SPATA33. In some embodiments, the human SPATA33 comprises the sequence of SEQ ID NO: 4410.

[0192] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 492 to 495 for binding to SPATA33, wherein the antibody binds to human SPATA33 or murine SPATA33.

[0193] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 636, a CDR-H2 of SEQ ID NO: 1178, and a CDR-H3 of SEQ ID NO: 1720, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 907, a CDR-L2 of SEQ ID NO: 1449, and a CDR-L3 of SEQ ID NO: 1991; Provided herein are antibodies or antigen-binding fragments thereof that selectively bind to ATPase secretory pathway Ca2+ transporter 1 (ATP2C1) or a variant thereof, including one of: In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 94, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ATP2C1, mouse ATP2C1, rat ATP2C1, bovine ATP2C1, or cynomolgus ATP2C1. In some embodiments, the human ATP2C1 comprises the sequence of SEQ ID NO: 4411.

[0194] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 497-500 for binding to ATP2C1, wherein the antibody binds to human ATP2C1 or mouse ATP2C1.

[0195] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to T-shirt zinc finger homeobox 2, transcript variant 1 (TSHZ2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 636, a CDR-H2 of SEQ ID NO: 1178, and a CDR-H3 of SEQ ID NO: 1720, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 907, a CDR-L2 of SEQ ID NO: 1449, and a CDR-L3 of SEQ ID NO: 1991. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 94, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 365. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TSHZ2, mouse TSHZ2, rat TSHZ2, bovine TSHZ2, or cynomolgus monkey TSHZ2. In some embodiments, the human TSHZ2 comprises the sequence of SEQ ID NO: 4412.

[0196] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 502-505 for binding to TSHZ2, wherein the antibody binds to human TSHZ2 or mouse TSHZ2.

[0197] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to complement component 4 binding protein beta (C4BPB) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 639, a CDR-H2 of SEQ ID NO: 1181, and a CDR-H3 of SEQ ID NO: 1723, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 910, a CDR-L2 of SEQ ID NO: 1452, and a CDR-L3 of SEQ ID NO: 1994. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 97, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody or antigen-binding fragment thereof binds to human C4BPB, mouse C4BPB, rat C4BPB, bovine C4BPB, or cynomolgus monkey C4BPB. In some embodiments, the human C4BPB comprises the sequence of SEQ ID NO: 4413.

[0198] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 507-510 for binding to C4BPB, wherein the antibody binds to human C4BPB or mouse C4BPB.

[0199] Complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 640, CDR of SEQ ID NO: 1182 Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to NCCRP1, F-box related domain-containing (NCCRP1), or a variant thereof, comprising at least one of a variable heavy chain region comprising CDR-H2, and CDR-H3 of SEQ ID NO: 1724, and a variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 911, CDR-L2 of SEQ ID NO: 1453, and CDR-L3 of SEQ ID NO: 1995. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 98, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 369. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NCCRP1, mouse NCCRP1, rat NCCRP1, bovine NCCRP1, or cynomolgus monkey NCCRP1. In some embodiments, the human NCCRP1 comprises the sequence of SEQ ID NO: 4414.

[0200] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 512-515 for binding to NCCRP1, wherein the antibody binds to human NCCRP1 or murine NCCRP1.

[0201] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to coiled-coil domain-containing 102A, transcript variant X1 (CCDC102A) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 640, a CDR-H2 of SEQ ID NO: 1182, and a CDR-H3 of SEQ ID NO: 1724, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 911, a CDR-L2 of SEQ ID NO: 1453, and a CDR-L3 of SEQ ID NO: 1995. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 98, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 369. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CCDC102A, mouse CCDC102A, rat CCDC102A, bovine CCDC102A, or cynomolgus CCDC102A. In some embodiments, the human CCDC102A comprises the sequence of SEQ ID NO: 4415.

[0202] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 517 to 520 for binding to CCDC102A, wherein the antibody binds to human CCDC102A or mouse CCDC102A.

[0203] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RNA-binding motif protein 47, transcript variant X10 (RBM47) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 641, a CDR-H2 of SEQ ID NO: 1183, and a CDR-H3 of SEQ ID NO: 1725, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 912, a CDR-L2 of SEQ ID NO: 1454, and a CDR-L3 of SEQ ID NO: 1996. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 99, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 370. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RBM47, mouse RBM47, rat RBM47, bovine RBM47, or cynomolgus RBM47. In some embodiments, the human RBM47 comprises the sequence of SEQ ID NO: 4416.

[0204] The antibody or antibody according to any one of claims 522 to 525 for binding to RBM47 Provided herein are antibodies that compete with antigen-binding fragments, which antibodies bind to human RBM47 or mouse RBM47.

[0205] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RAD1 checkpoint DNA exonuclease, transcript variant 1 (RAD1), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 643, a CDR-H2 of SEQ ID NO: 1185, and a CDR-H3 of SEQ ID NO: 1727, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 914, a CDR-L2 of SEQ ID NO: 1456, and a CDR-L3 of SEQ ID NO: 1998. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 101, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 372. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RAD1, mouse RAD1, rat RAD1, bovine RAD1, or cynomolgus RAD1. In some embodiments, the human RAD1 comprises the sequence of SEQ ID NO: 4417.

[0206] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 527-530 for binding to RAD1, wherein the antibody binds to human RAD1 or murine RAD1.

[0207] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule-associated scaffold protein 1 (MTUS1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 643, a CDR-H2 of SEQ ID NO: 1185, and a CDR-H3 of SEQ ID NO: 1727, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 914, a CDR-L2 of SEQ ID NO: 1456, and a CDR-L3 of SEQ ID NO: 1998. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 101, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 372. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MTUS1, mouse MTUS1, rat MTUS1, bovine MTUS1, or cynomolgus MTUS1. In some embodiments, the human MTUS1 comprises the sequence of SEQ ID NO: 4418.

[0208] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 532 to 535 for binding to MTUS1, wherein the antibody binds to human MTUS1 or mouse MTUS1.

[0209] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kelch-like ECH-associated protein 1, transcript variant 1 (KEAP1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 645, a CDR-H2 of SEQ ID NO: 1187, and a CDR-H3 of SEQ ID NO: 1729, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 916, a CDR-L2 of SEQ ID NO: 1458, and a CDR-L3 of SEQ ID NO: 2000. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 103, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 374. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KEAP1, mouse KEAP1, rat KEAP1, bovine KEAP1, or cynomolgus KEAP1. In some embodiments, human KEAP1 comprises the sequence of SEQ ID NO: 4385. .

[0210] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 537-540 for binding to KEAP1, wherein the antibody binds to human KEAP1 or mouse KEAP1.

[0211] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PNMA family member 5, transcript variant 2 (PNMA5) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 646, a CDR-H2 of SEQ ID NO: 1188, and a CDR-H3 of SEQ ID NO: 1730, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 917, a CDR-L2 of SEQ ID NO: 1459, and a CDR-L3 of SEQ ID NO: 2001. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 104, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PNMA5, mouse PNMA5, rat PNMA5, bovine PNMA5, or cynomolgus PNMA5. In some embodiments, the human PNMA5 comprises the sequence of SEQ ID NO:4357.

[0212] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 542-545 for binding to PNMA5, wherein the antibody binds to human PNMA5 or murine PNMA5.

[0213] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to G protein-coupled receptor 83, transcript variant 1 (GPR83), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 650, a CDR-H2 of SEQ ID NO: 1192, and a CDR-H3 of SEQ ID NO: 1734, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 921, a CDR-L2 of SEQ ID NO: 1463, and a CDR-L3 of SEQ ID NO: 2005. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 108, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 379. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GPR83, mouse GPR83, rat GPR83, bovine GPR83, or cynomolgus monkey GPR83. In some embodiments, the human GPR83 comprises the sequence of SEQ ID NO: 4419.

[0214] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 547-550 for binding to GPR83, wherein the antibody binds to human GPR83 or murine GPR83.

[0215] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to CDP-diacylglycerol synthase 1 (CDS1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 651, a CDR-H2 of SEQ ID NO: 1193, and a CDR-H3 of SEQ ID NO: 1735, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 922, a CDR-L2 of SEQ ID NO: 1464, and a CDR-L3 of SEQ ID NO: 2006. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 109, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody or antigen-binding fragment thereof selectively binds to human CDS1, mouse CDS1, or a variant thereof. S1, rat CDS1, bovine CDS1, or cynomolgus CDS1. In some embodiments, the human CDS1 comprises the sequence of SEQ ID NO: 4420.

[0216] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 552-555 for binding to CDS1, wherein the antibody binds to human CDS1 or murine CDS1.

[0217] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to dynein axoneme assembly factor 3, transcript variant 3 (DNAAF3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 651, a CDR-H2 of SEQ ID NO: 1193, and a CDR-H3 of SEQ ID NO: 1735, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 922, a CDR-L2 of SEQ ID NO: 1464, and a CDR-L3 of SEQ ID NO: 2006. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 109, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DNAAF3, mouse DNAAF3, rat DNAAF3, bovine DNAAF3, or cynomolgus DNAAF3. In some embodiments, the human DNAAF3 comprises the sequence of SEQ ID NO: 4421.

[0218] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 557-560 for binding to DNAAF3, wherein the antibody binds to human DNAAF3 or mouse DNAAF3.

[0219] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Copine 1, transcript variant 2 (CPNE1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 652, a CDR-H2 of SEQ ID NO: 1194, and a CDR-H3 of SEQ ID NO: 1736, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 923, a CDR-L2 of SEQ ID NO: 1465, and a CDR-L3 of SEQ ID NO: 2007. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 110, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 381. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CPNE1, mouse CPNE1, rat CPNE1, bovine CPNE1, or cynomolgus CPNE1. In some embodiments, the human CPNE1 comprises the sequence of SEQ ID NO:4422.

[0220] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 562 to 565 for binding to CPNE1, wherein the antibody binds to human CPNE1 or mouse CPNE1.

[0221] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to aarF domain-containing kinase 5 (ADCK5) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 653, a CDR-H2 of SEQ ID NO: 1195, and a CDR-H3 of SEQ ID NO: 1737, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 924, a CDR-L2 of SEQ ID NO: 1466, and a CDR-L3 of SEQ ID NO: 2008. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 111, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 382. The antibody or antigen-binding fragment thereof binds to human ADCK5, mouse ADCK5, rat ADCK5, bovine ADCK5, or cynomolgus ADCK5. In some embodiments, the human ADCK5 comprises the sequence of SEQ ID NO: 4423.

[0222] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 567-570 for binding to ADCK5, wherein the antibody binds to human ADCK5 or murine ADCK5.

[0223] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to crystallin alpha B, transcript variant 2 (CRYAB) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 655, a CDR-H2 of SEQ ID NO: 1197, and a CDR-H3 of SEQ ID NO: 1739, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 926, a CDR-L2 of SEQ ID NO: 1468, and a CDR-L3 of SEQ ID NO: 2010. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 113, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 384. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CRYAB, mouse CRYAB, rat CRYAB, bovine CRYAB, or cynomolgus CRYAB. In some embodiments, the human CRYAB comprises the sequence of SEQ ID NO:4424.

[0224] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 572 to 575 for binding to CRYAB, wherein the antibody binds to human CRYAB or mouse CRYAB.

[0225] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hematopoietic cell-specific Lyn substrate 1, transcript variant 1 (HCLS1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 656, a CDR-H2 of SEQ ID NO: 1198, and a CDR-H3 of SEQ ID NO: 1740, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 927, a CDR-L2 of SEQ ID NO: 1469, and a CDR-L3 of SEQ ID NO: 2011. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 114, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 385. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HCLS1, mouse HCLS1, rat HCLS1, bovine HCLS1, or cynomolgus HCLS1. In some embodiments, the human HCLS1 comprises the sequence of SEQ ID NO: 4425.

[0226] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 577 to 580 for binding to HCLS1, wherein the antibody binds to human HCLS1 or mouse HCLS1.

[0227] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to aldo-keto reductase family 1 member B, transcript variant 1 (AKR1B1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 657, a CDR-H2 of SEQ ID NO: 1199, and a CDR-H3 of SEQ ID NO: 1741, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 928, a CDR-L2 of SEQ ID NO: 1470, and a CDR-L3 of SEQ ID NO: 2012. In some embodiments, the variable heavy chain has an amino acid sequence similar to at least that of SEQ ID NO: 115. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 386. In some embodiments, the antibody or antigen-binding fragment thereof binds to human AKR1B1, mouse AKR1B1, rat AKR1B1, bovine AKR1B1, or cynomolgus AKR1B1. In some embodiments, the human AKR1B1 comprises the sequence of SEQ ID NO: 4426.

[0228] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 582-585 for binding to AKR1B1, wherein the antibody binds to human AKR1B1 or murine AKR1B1.

[0229] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SURF6, transcript variant 1 (SURF6), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 658, a CDR-H2 of SEQ ID NO: 1200, and a CDR-H3 of SEQ ID NO: 1742, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 929, a CDR-L2 of SEQ ID NO: 1471, and a CDR-L3 of SEQ ID NO: 2013. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 116, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SURF6, mouse SURF6, rat SURF6, bovine SURF6, or cynomolgus SURF6. In some embodiments, the human SURF6 comprises the sequence of SEQ ID NO:4427.

[0230] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 587-590 for binding to SURF6, wherein the antibody binds to human SURF6 or murine SURF6.

[0231] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to proliferating cell nuclear antigen or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 658, a CDR-H2 of SEQ ID NO: 1200, and a CDR-H3 of SEQ ID NO: 1742, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 929, a CDR-L2 of SEQ ID NO: 1471, and a CDR-L3 of SEQ ID NO: 2013. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 116, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PCNA, mouse PCNA, rat PCNA, bovine PCNA, or cynomolgus PCNA. In some embodiments, the human PCNA comprises the sequence of SEQ ID NO:4428.

[0232] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 592-595 for binding to PCNA, wherein the antibody binds to human PCNA or mouse PCNA.

[0233] Selected is S100 calcium-binding protein B (S100B) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 663, a CDR-H2 of SEQ ID NO: 1205, and a CDR-H3 of SEQ ID NO: 1747, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 934, a CDR-L2 of SEQ ID NO: 1476, and a CDR-L3 of SEQ ID NO: 2018. Provided herein are antibodies or antigen-binding fragments thereof that specifically bind to S100B. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 121, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 392. In some embodiments, the antibody or antigen-binding fragment thereof binds to human S100B, mouse S100B, rat S100B, bovine S100B, or cynomolgus S100B. In some embodiments, the human S100B comprises the sequence of SEQ ID NO: 4429.

[0234] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 597-600 for binding to S100B, wherein the antibody binds to human S100B or mouse S100B.

[0235] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to checkpoint kinase 2, transcript variant 3 (CHEK2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 664, a CDR-H2 of SEQ ID NO: 1206, and a CDR-H3 of SEQ ID NO: 1748, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 935, a CDR-L2 of SEQ ID NO: 1477, and a CDR-L3 of SEQ ID NO: 2019. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 122, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 393. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CHEK2, mouse CHEK2, rat CHEK2, bovine CHEK2, or cynomolgus CHEK2. In some embodiments, the human CHEK2 comprises the sequence of SEQ ID NO:4430.

[0236] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 602-605 for binding to CHEK2, wherein the antibody binds to human CHEK2 or murine CHEK2.

[0237] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ankyrin repeat domain 53, transcript variant 2 (ANKRD53) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 670, a CDR-H2 of SEQ ID NO: 1212, and a CDR-H3 of SEQ ID NO: 1754, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 941, a CDR-L2 of SEQ ID NO: 1483, and a CDR-L3 of SEQ ID NO: 2025. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 128,

[0238] The variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 399. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ANKRD53, mouse ANKRD53, rat ANKRD53, bovine ANKRD53, or cynomolgus monkey ANKRD53. In some embodiments, the human ANKRD53 comprises the sequence of SEQ ID NO: 4431.

[0239] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 607-610 for binding to ANKRD53, wherein the antibody binds to human ANKRD53 or murine ANKRD53.

[0240] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767, and / or Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to killer cell lectin-like receptor g2 (KLRG2) or a variant thereof, comprising at least one variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, CDR-L2 of SEQ ID NO: 1496, and CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KLRG2, mouse KLRG2, rat KLRG2, bovine KLRG2, or cynomolgus monkey KLRG2. In some embodiments, the human KLRG2 comprises the sequence of SEQ ID NO: 4432.

[0241] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 612-615 for binding to KLRG2, wherein the antibody binds to human KLRG2 or mouse KLRG2.

[0242] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to tripartite motif-containing 35, transcript variant 1 (TRIM35) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, a CDR-L2 of SEQ ID NO: 1496, and a CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TRIM35, mouse TRIM35, rat TRIM35, bovine TRIM35, or cynomolgus monkey TRIM35. In some embodiments, the human TRIM35 comprises the sequence of SEQ ID NO: 4433.

[0243] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 617 to 620 for binding to TRIM35, wherein the antibody binds to human TRIM35 or murine TRIM35.

[0244] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to FMR1 autosomal homolog 2 (FXR2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 683, a CDR-H2 of SEQ ID NO: 1225, and a CDR-H3 of SEQ ID NO: 1767, and a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 954, a CDR-L2 of SEQ ID NO: 1496, and a CDR-L3 of SEQ ID NO: 2038. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 141, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 412. In some embodiments, the antibody or antigen-binding fragment thereof binds to human FXR2, mouse FXR2, rat FXR2, bovine FXR2, or cynomolgus FXR2. In some embodiments, the human FXR2 comprises the sequence of SEQ ID NO:4434.

[0245] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 622-625 for binding to FXR2, wherein the antibody binds to human FXR2 or mouse FXR2.

[0246] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to annexin A1 (ANXA1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 686, a CDR-H2 of SEQ ID NO: 1228, and a CDR-H3 of SEQ ID NO: 1770, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 957, a CDR-L2 of SEQ ID NO: 1499, and a CDR-L3 of SEQ ID NO: 2041. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 144, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ANXA1, mouse ANXA1, rat ANXA1, bovine ANXA1, or cynomolgus monkey ANXA1. In some embodiments, the human ANXA1 comprises the sequence of SEQ ID NO: 4435.

[0247] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 627-630 for binding to ANXA1, wherein the antibody binds to human ANXA1 or mouse ANXA1.

[0248] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 287, transcript variant 2 (ZNF287), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 690, a CDR-H2 of SEQ ID NO: 1232, and a CDR-H3 of SEQ ID NO: 1774, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 961, a CDR-L2 of SEQ ID NO: 1503, and a CDR-L3 of SEQ ID NO: 2045. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 148, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 419. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF287, mouse ZNF287, rat ZNF287, bovine ZNF287, or cynomolgus ZNF287. In some embodiments, the human ZNF287 comprises the sequence of SEQ ID NO: 4436.

[0249] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 632-635 for binding to ZNF287, wherein the antibody binds to human ZNF287 or murine ZNF287.

[0250] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Family 177 member A1, transcript variant 2 (FAM177A1) or a variant thereof with sequence similarity, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 698, a CDR-H2 of SEQ ID NO: 1240, and a CDR-H3 of SEQ ID NO: 1782, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 969, a CDR-L2 of SEQ ID NO: 1511, and a CDR-L3 of SEQ ID NO: 2053. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 156, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 427. In some embodiments, the antibody or antigen-binding fragment thereof binds to human FAM177A1, mouse FAM177A1, rat FAM177A1, bovine FAM177A1, or cynomolgus monkey FAM177A1. In some embodiments, the human FAM177A1 comprises the sequence of SEQ ID NO: 4437.

[0251] The antibody according to any one of claims 637 to 640 for binding to FAM177A1 Alternatively, provided herein are antibodies that compete with antigen-binding fragments, which antibodies bind to human FAM177A1 or murine FAM177A1.

[0252] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to quinoid dihydropteridine reductase, transcript variant 1 (QDPR), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 701, a CDR-H2 of SEQ ID NO: 1243, and a CDR-H3 of SEQ ID NO: 1785, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 972, a CDR-L2 of SEQ ID NO: 1514, and a CDR-L3 of SEQ ID NO: 2056. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 159, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 430. In some embodiments, the antibody or antigen-binding fragment thereof binds to human QDPR, mouse QDPR, rat QDPR, bovine QDPR, or cynomolgus QDPR. In some embodiments, the human QDPR comprises the sequence of SEQ ID NO: 4438.

[0253] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 642-645 for binding to QDPR, wherein the antibody binds to human QDPR or mouse QDPR.

[0254] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ELK2, a member of the ETS oncogene family, pseudogene 1 (BC031259.1_frag), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 703, a CDR-H2 of SEQ ID NO: 1245, and a CDR-H3 of SEQ ID NO: 1787, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 974, a CDR-L2 of SEQ ID NO: 1516, and a CDR-L3 of SEQ ID NO: 2058. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 161, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 432. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BC031259.1_frag, mouse BC031259.1_frag, rat BC031259.1_frag, bovine BC031259.1_frag, or cynomolgus monkey BC031259.1_frag. In some embodiments, human BC031259.1_frag comprises the sequence of SEQ ID NO: 4439.

[0255] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 647-650 for binding to BC031259.1_frag, wherein the antibody binds to human BC031259.1_frag or murine BC031259.1_frag.

[0256] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to methyltransferase-like 21C (METTL21C) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 703, a CDR-H2 of SEQ ID NO: 1245, and a CDR-H3 of SEQ ID NO: 1787, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 974, a CDR-L2 of SEQ ID NO: 1516, and a CDR-L3 of SEQ ID NO: 2058. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 161, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 432. In some embodiments, the antibody or antigen-binding fragment thereof selectively binds to human METTL21C, ... In some embodiments, human METTL21C comprises the sequence of SEQ ID NO:4440.

[0257] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 652-655 for binding to METTL21C, wherein the antibody binds to human METTL21C or mouse METTL21C.

[0258] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to hydroxymethylbilane synthase, transcript variant X3 (HMBS), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 706, a CDR-H2 of SEQ ID NO: 1248, and a CDR-H3 of SEQ ID NO: 1790, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 977, a CDR-L2 of SEQ ID NO: 1519, and a CDR-L3 of SEQ ID NO: 2061. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 164, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 435. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HMBS, mouse HMBS, rat HMBS, bovine HMBS, or cynomolgus monkey HMBS. In some embodiments, the human HMBS comprises the sequence of SEQ ID NO: 4441.

[0259] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 657-660 for binding to HMBS, wherein the antibody binds to human HMBS or murine HMBS.

[0260] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Hook microtubule-associated protein 2, transcript variant 2 (HOOK2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 706, a CDR-H2 of SEQ ID NO: 1248, and a CDR-H3 of SEQ ID NO: 1790, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 977, a CDR-L2 of SEQ ID NO: 1519, and a CDR-L3 of SEQ ID NO: 2061. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 164, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 435. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HOOK2, mouse HOOK2, rat HOOK2, bovine HOOK2, or cynomolgus HOOK2. In some embodiments, the human HOOK2 comprises the sequence of SEQ ID NO: 4442.

[0261] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 662-665 for binding to HOOK2, wherein the antibody binds to human HOOK2 or murine HOOK2.

[0262] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Magel2(Q6ir13_frag) or a variant thereof, comprising at least one of the following:

[0263] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 713, a CDR-H2 of SEQ ID NO: 1255, and a CDR-H3 of SEQ ID NO: 1797, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 984, a CDR-L2 of SEQ ID NO: 1526, and a CDR-L3 of SEQ ID NO: 2068. In some embodiments, the variable heavy chain has at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 171. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 442. In some embodiments, the antibody or antigen-binding fragment thereof binds to human Q6ir13_frag, mouse Q6ir13_frag, rat Q6ir13_frag, bovine Q6ir13_frag, or cynomolgus monkey Q6ir13_frag. In some embodiments, the human Q6ir13_frag comprises the sequence of SEQ ID NO: 4443.

[0264] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 667-670 for binding to Q6ir13_frag, wherein the antibody binds to human Q6ir13_frag or mouse Q6ir13_frag.

[0265] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serine- and arginine-rich splicing factor 3, transcript variant 1 (SRSF3), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 713, a CDR-H2 of SEQ ID NO: 1255, and a CDR-H3 of SEQ ID NO: 1797, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 984, a CDR-L2 of SEQ ID NO: 1526, and a CDR-L3 of SEQ ID NO: 2068. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 171, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 442. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SRSF3, mouse SRSF3, rat SRSF3, bovine SRSF3, or cynomolgus monkey SRSF3. In some embodiments, the human SRSF3 comprises the sequence of SEQ ID NO: 4444.

[0266] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 672-675 for binding to SRSF3, wherein the antibody binds to human SRSF3 or mouse SRSF3.

[0267] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RAN binding protein 10, transcript variant 1 (RANBP10), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 714, a CDR-H2 of SEQ ID NO: 1256, and a CDR-H3 of SEQ ID NO: 1798, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 985, a CDR-L2 of SEQ ID NO: 1527, and a CDR-L3 of SEQ ID NO: 2069. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 172, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RANBP10, mouse RANBP10, rat RANBP10, bovine RANBP10, or cynomolgus monkey RANBP10. In some embodiments, the human RANBP10 comprises the sequence of SEQ ID NO: 4445.

[0268] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 677 to 680 for binding to RANBP10, wherein the antibody binds to human RANBP10 or mouse RANBP10.

[0269] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 714, a CDR-H2 of SEQ ID NO: 1256, and a CDR-H3 of SEQ ID NO: 1798, and / or a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 985, a CDR- Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Wnt family member 9b (WNT9B) or a variant thereof, comprising at least one of a variable heavy chain region comprising CDR-L2, and a variable light chain region comprising CDR-L3 of SEQ ID NO: 2069. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 172, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody or antigen-binding fragment thereof binds to human WNT9B, mouse WNT9B, rat WNT9B, bovine WNT9B, or cynomolgus monkey WNT9B. In some embodiments, the human WNT9B comprises the sequence of SEQ ID NO: 4446.

[0270] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 682-685 for binding to WNT9B, wherein the antibody binds to human WNT9B or murine WNT9B.

[0271] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquilin 2 (UBQLN2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds to human UBQLN2, mouse UBQLN2, rat UBQLN2, bovine UBQLN2, or cynomolgus monkey UBQLN2. In some embodiments, the human UBQLN2 comprises the sequence of SEQ ID NO: 4447.

[0272] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 687-690 for binding to UBQLN2, wherein the antibody binds to human UBQLN2 or murine UBQLN2.

[0273] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquilin 1, transcript variant 2 (UBQLN1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds to human UBQLN1, mouse UBQLN1, rat UBQLN1, bovine UBQLN1, or cynomolgus monkey UBQLN1. In some embodiments, the human UBQLN1 comprises the sequence of SEQ ID NO: 4370.

[0274] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 692-695 for binding to UBQLN1, wherein the antibody binds to human UBQLN1 or mouse UBQLN1.

[0275] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 715, a CDR-H2 of SEQ ID NO: 1257, and a CDR-H3 of SEQ ID NO: 1799; and / or Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ubiquilin 3 (UBQLN3) or a variant thereof, comprising at least one of a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 986, a CDR-L2 of SEQ ID NO: 1528, and a CDR-L3 of SEQ ID NO: 2070. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 444. In some embodiments, the antibody or antigen-binding fragment thereof binds to human UBQLN3, mouse UBQLN3, rat UBQLN3, bovine UBQLN3, or cynomolgus monkey UBQLN3. In some embodiments, the human UBQLN3 comprises the sequence of SEQ ID NO: 4448.

[0276] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 697-700 for binding to UBQLN3, wherein the antibody binds to human UBQLN3 or mouse UBQLN3.

[0277] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to forward gradient 3, a protein disulfide isomerase family member (AGR3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 717, a CDR-H2 of SEQ ID NO: 1259, and a CDR-H3 of SEQ ID NO: 1801, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 988, a CDR-L2 of SEQ ID NO: 1530, and a CDR-L3 of SEQ ID NO: 2072. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 175, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 446. In some embodiments, the antibody or antigen-binding fragment thereof binds to human AGR3, mouse AGR3, rat AGR3, bovine AGR3, or cynomolgus monkey AGR3. In some embodiments, the human AGR3 comprises the sequence of SEQ ID NO: 4449.

[0278] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 702-705 for binding to AGR3, wherein the antibody binds to human AGR3 or mouse AGR3.

[0279] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serine- and arginine-rich splicing factor 3, transcript variant 1 (SRSF3), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 719, a CDR-H2 of SEQ ID NO: 1261, and a CDR-H3 of SEQ ID NO: 1803, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 990, a CDR-L2 of SEQ ID NO: 1532, and a CDR-L3 of SEQ ID NO: 2074. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 177, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 448. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SRSF3, mouse SRSF3, rat SRSF3, bovine SRSF3, or cynomolgus monkey SRSF3. In some embodiments, the human SRSF3 comprises the sequence of SEQ ID NO: 4444.

[0280] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 707 to 710 for binding to SRSF3, wherein the antibody binds to human SRSF3 or mouse SRSF3.

[0281] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to baculovirus IAP repeat-containing 7, transcript variant 1 (BIRC7) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 720, a CDR-H2 of SEQ ID NO: 1262, and a CDR-H3 of SEQ ID NO: 1804, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 991, a CDR-L2 of SEQ ID NO: 1533, and a CDR-L3 of SEQ ID NO: 2075. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 178, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 449. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BIRC7, mouse BIRC7, rat BIRC7, bovine BIRC7, or cynomolgus monkey BIRC7. In some embodiments, the human BIRC7 comprises the sequence of SEQ ID NO: 4450.

[0282] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 712 to 715 for binding to BIRC7, wherein the antibody binds to human BIRC7 or mouse BIRC7.

[0283] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosomal-associated transport regulator 1, transcript variant 2 (SDCCAG3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 722, a CDR-H2 of SEQ ID NO: 1264, and a CDR-H3 of SEQ ID NO: 1806, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 993, a CDR-L2 of SEQ ID NO: 1535, and a CDR-L3 of SEQ ID NO: 2077. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 180, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 451. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3, or cynomolgus SDCCAG3. In some embodiments, the human SDCCAG3 comprises the sequence of SEQ ID NO: 4373.

[0284] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 717-720 for binding to SDCCAG3, wherein the antibody binds to human SDCCAG3 or murine SDCCAG3.

[0285] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule-associated scaffold protein 2, transcript variant 2 (MTUS2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 724, a CDR-H2 of SEQ ID NO: 1266, and a CDR-H3 of SEQ ID NO: 1808, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 995, a CDR-L2 of SEQ ID NO: 1537, and a CDR-L3 of SEQ ID NO: 2079. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 182, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 453. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MTUS2, mouse MTUS2, rat MTUS2, bovine MTUS2, or cynomolgus MTUS2. In some embodiments, the human MTUS2 comprises the sequence of SEQ ID NO: 4451.

[0286] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 722 to 725 for binding to MTUS2, wherein the antibody binds to human MTUS2 or mouse MTUS2.

[0287] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 296 (ZNF296) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF296, mouse ZNF296, rat ZNF296, bovine ZNF296, or cynomolgus ZNF296. In some embodiments, the human ZNF296 comprises the sequence of SEQ ID NO: 4452.

[0288] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 727-730 for binding to ZNF296, wherein the antibody binds to human ZNF296 or murine ZNF296.

[0289] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phosphodiesterase 5A, transcript variant 1 (PDE5A), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PDE5A, mouse PDE5A, rat PDE5A, bovine PDE5A, or cynomolgus PDE5A. In some embodiments, the human PDE5A comprises the sequence of SEQ ID NO: 4453.

[0290] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 732-735 for binding to PDE5A, wherein the antibody binds to human PDE5A or murine PDE5A.

[0291] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Ep400 pseudogene 1 (EP400NL) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 725, a CDR-H2 of SEQ ID NO: 1267, and a CDR-H3 of SEQ ID NO: 1809, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 996, a CDR-L2 of SEQ ID NO: 1538, and a CDR-L3 of SEQ ID NO: 2080. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 183, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 454. In some embodiments, the antibody or antigen-binding fragment thereof is directed against human EP400NL, mouse EP400NL, rat EP400NL, bovine EP400NL, or cynomolgus EP400NL. In some embodiments, human EP400NL comprises the sequence of SEQ ID NO:4454.

[0292] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 737 to 740 for binding to EP400NL, wherein the antibody binds to human EP400NL or murine EP400NL.

[0293] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Bcl2-like 1 (BCL2L1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 727, a CDR-H2 of SEQ ID NO: 1269, and a CDR-H3 of SEQ ID NO: 1811, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 998, a CDR-L2 of SEQ ID NO: 1540, and a CDR-L3 of SEQ ID NO: 2082. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 456. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BCL2L1, mouse BCL2L1, rat BCL2L1, bovine BCL2L1, or cynomolgus BCL2L1. In some embodiments, the human BCL2L1 comprises the sequence of SEQ ID NO: 4455.

[0294] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 742-745 for binding to BCL2L1, wherein the antibody binds to human BCL2L1 or murine BCL2L1.

[0295] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Arginine- and Glutamine-Rich 1 (ARGLU1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 728, a CDR-H2 of SEQ ID NO: 1270, and a CDR-H3 of SEQ ID NO: 1812, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 999, a CDR-L2 of SEQ ID NO: 1541, and a CDR-L3 of SEQ ID NO: 2083. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 457. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ARGLU1, mouse ARGLU1, rat ARGLU1, bovine ARGLU1, or cynomolgus monkey ARGLU1. In some embodiments, the human ARGLU1 comprises the sequence of SEQ ID NO: 4456.

[0296] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 747-750 for binding to ARGLU1, wherein the antibody binds to human ARGLU1 or mouse ARGLU1.

[0297] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SAS-6 centriole assembly protein, transcript variant 2 (SASS6) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 728, a CDR-H2 of SEQ ID NO: 1270, and a CDR-H3 of SEQ ID NO: 1812, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 999, a CDR-L2 of SEQ ID NO: 1541, and a CDR-L3 of SEQ ID NO: 2083. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 457. The antibody or antigen-binding fragment thereof comprises a polypeptide consensus sequence having at least 95% sequence identity with the amino acid sequence of human SASS6, mouse SASS6, rat SASS6, bovine SASS6, or cynomolgus monkey SASS6. In some embodiments, the human SASS6 comprises the sequence of SEQ ID NO: 4457.

[0298] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 752-755 for binding to SASS6, wherein the antibody binds to human SASS6 or murine SASS6.

[0299] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to non-ATPase 4, transcript variant 2 (PSMD4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 729, a CDR-H2 of SEQ ID NO: 1271, and a CDR-H3 of SEQ ID NO: 1813, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1000, a CDR-L2 of SEQ ID NO: 1542, and a CDR-L3 of SEQ ID NO: 2084. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 458. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PSMD4, mouse PSMD4, rat PSMD4, bovine PSMD4, or cynomolgus PSMD4. In some embodiments, the human PSMD4 comprises the sequence of SEQ ID NO: 4458.

[0300] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 757-760 for binding to PSMD4, wherein the antibody binds to human PSMD4 or murine PSMD4.

[0301] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Src-like adaptor, transcript variant 1 (SLA), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 729, a CDR-H2 of SEQ ID NO: 1271, and a CDR-H3 of SEQ ID NO: 1813, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1000, a CDR-L2 of SEQ ID NO: 1542, and a CDR-L3 of SEQ ID NO: 2084. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 458. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SLA, mouse SLA, rat SLA, bovine SLA, or cynomolgus SLA. In some embodiments, the human SLA comprises the sequence of SEQ ID NO:4459.

[0302] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 762-765 for binding to SLA, wherein the antibody binds to human SLA or murine SLA.

[0303] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Nudix hydrolase 21 (NUDT21) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, wherein the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NUDT21, mouse NUDT21, rat NUDT21, bovine NUDT21, or cynomolgus monkey NUDT21. In some embodiments, the human NUDT21 comprises the sequence of SEQ ID NO: 4460.

[0304] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 767 to 770 for binding to NUDT21, wherein the antibody binds to human NUDT21 or mouse NUDT21.

[0305] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 431, transcript variant 2 (ZNF431), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF431, mouse ZNF431, rat ZNF431, bovine ZNF431, or cynomolgus ZNF431. In some embodiments, the human ZNF431 comprises the sequence of SEQ ID NO: 4461.

[0306] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 772-775 for binding to ZNF431, wherein the antibody binds to human ZNF431 or murine ZNF431.

[0307] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to zinc finger protein 699 (ZNF699) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 582, a CDR-H2 of SEQ ID NO: 1124, and a CDR-H3 of SEQ ID NO: 1666, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 853, a CDR-L2 of SEQ ID NO: 1395, and a CDR-L3 of SEQ ID NO: 1937. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 459. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ZNF699, mouse ZNF699, rat ZNF699, bovine ZNF699, or cynomolgus ZNF699. In some embodiments, the human ZNF699 comprises the sequence of SEQ ID NO: 4462.

[0308] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 777-780 for binding to ZNF699, wherein the antibody binds to human ZNF699 or murine ZNF699.

[0309] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 731, a CDR-H2 of SEQ ID NO: 1273, and a CDR-H3 of SEQ ID NO: 1815, and / or a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1002, a CDR of SEQ ID NO: 1544 Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to quinoid dihydropteridine reductase, transcript variant 1 (QDPR) or a variant thereof, comprising at least one of a variable heavy chain region comprising CDR-L2, and a variable light chain region comprising CDR-L3 of SEQ ID NO: 2086. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 460. In some embodiments, the antibody or antigen-binding fragment thereof binds to human QDPR, mouse QDPR, rat QDPR, bovine QDPR, or cynomolgus monkey QDPR. In some embodiments, the human QDPR comprises the sequence of SEQ ID NO: 4438.

[0310] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 782-785 for binding to QDPR, wherein the antibody binds to human QDPR or murine QDPR.

[0311] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to PAGE family member 2 (PAGE2) or a variant thereof, comprising at least one of the following: a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 732, a CDR-H2 of SEQ ID NO: 1274, and a CDR-H3 of SEQ ID NO: 1816, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1003, a CDR-L2 of SEQ ID NO: 1545, and a CDR-L3 of SEQ ID NO: 2087. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 461. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PAGE2, mouse PAGE2, rat PAGE2, bovine PAGE2, or cynomolgus PAGE2. In some embodiments, the human PAGE2 comprises the sequence of SEQ ID NO: 4463.

[0312] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 787-790 for binding to PAGE2, wherein the antibody binds to human PAGE2 or murine PAGE2.

[0313] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to keratin-associated protein 12-3 (KRTAP12-3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 732, a CDR-H2 of SEQ ID NO: 1274, and a CDR-H3 of SEQ ID NO: 1816, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1003, a CDR-L2 of SEQ ID NO: 1545, and a CDR-L3 of SEQ ID NO: 2087. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 461. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KRTAP12-3, mouse KRTAP12-3, rat KRTAP12-3, bovine KRTAP12-3, or cynomolgus KRTAP12-3. In some embodiments, the human KRTAP12-3 comprises the sequence of SEQ ID NO: 4464.

[0314] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 792-795 for binding to KRTAP12-3, wherein the antibody binds to human KRTAP12-3 or murine KRTAP12-3.

[0315] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to enolase 2 (ENO2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 734, a CDR-H2 of SEQ ID NO: 1276, and a CDR-H3 of SEQ ID NO: 1818, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1005, a CDR-L2 of SEQ ID NO: 1547, and a CDR-L3 of SEQ ID NO: 2089. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 463. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ENO2, mouse ENO2, rat ENO2, bovine ENO2, or cynomolgus ENO2. In some embodiments, the human ENO2 comprises the sequence of SEQ ID NO: 4465.

[0316] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 797 to 800 for binding to ENO2, wherein the antibody binds to human ENO2 or mouse ENO2.

[0317] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to chromosome 11 open reading frame 68, transcript variant 1 (C11orf68) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 734, a CDR-H2 of SEQ ID NO: 1276, and a CDR-H3 of SEQ ID NO: 1818, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1005, a CDR-L2 of SEQ ID NO: 1547, and a CDR-L3 of SEQ ID NO: 2089. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 463. In some embodiments, the antibody or antigen-binding fragment thereof binds to human C11orf68, mouse C11orf68, rat C11orf68, bovine C11orf68, or cynomolgus monkey C11orf68. In some embodiments, the human C11orf68 comprises the sequence of SEQ ID NO: 4466.

[0318] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 802 to 805 for binding to C11orf68, wherein the antibody binds to human C11orf68 or mouse C11orf68.

[0319] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to methionyl-tRNA synthetase 1 (MARS) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 735, a CDR-H2 of SEQ ID NO: 1277, and a CDR-H3 of SEQ ID NO: 1819, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1006, a CDR-L2 of SEQ ID NO: 1548, and a CDR-L3 of SEQ ID NO: 2090. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 464. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MARS, mouse MARS, rat MARS, bovine MARS, or cynomolgus MARS. In some embodiments, the human MARS comprises the sequence of SEQ ID NO:4467.

[0320] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 807-810 for binding to MARS, the antibody comprising human MARS or mouse MARS. Binds to MARS.

[0321] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to serpin family B member 6, transcript variant 2 (SERPINB6) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 737, a CDR-H2 of SEQ ID NO: 1279, and a CDR-H3 of SEQ ID NO: 1821, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1008, a CDR-L2 of SEQ ID NO: 1550, and a CDR-L3 of SEQ ID NO: 2092. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 466. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SERPINB6, mouse SERPINB6, rat SERPINB6, bovine SERPINB6, or cynomolgus SERPINB6. In some embodiments, the human SERPINB6 comprises the sequence of SEQ ID NO: 4468.

[0322] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 812 to 815 for binding to SERPINB6, wherein the antibody binds to human SERPINB6 or mouse SERPINB6.

[0323] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endoplasmic reticulum protein 27, transcript variant 1 (ERP27) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ERP27, mouse ERP27, rat ERP27, bovine ERP27, or cynomolgus ERP27. In some embodiments, the human ERP27 comprises the sequence of SEQ ID NO: 4469.

[0324] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 817-820 for binding to ERP27, wherein the antibody binds to human ERP27 or murine ERP27.

[0325] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Dpy-30 histone methyltransferase complex regulatory subunit (DPY30) or a variant thereof, comprising at least one of the following:

[0326] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DPY30, mouse DPY30, rat DPY30, bovine DPY30, or cynomolgus DPY30. In some embodiments, the human DPY30 comprises the sequence of SEQ ID NO:4470.

[0327] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 822 to 825 for binding to DPY30, wherein the antibody binds to human DPY30 or mouse DPY30.

[0328] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to rhophilin-related tail protein 1-like, transcript variant 2 (ROPN1L) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 738, a CDR-H2 of SEQ ID NO: 1280, and a CDR-H3 of SEQ ID NO: 1822, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1009, a CDR-L2 of SEQ ID NO: 1551, and a CDR-L3 of SEQ ID NO: 2093. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 467. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ROPN1L, mouse ROPN1L, rat ROPN1L, bovine ROPN1L, or cynomolgus ROPN1L. In some embodiments, the human ROPN1L comprises the sequence of SEQ ID NO: 4471.

[0329] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 827-830 for binding to ROPN1L, wherein the antibody binds to human ROPN1L or mouse ROPN1L.

[0330] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endosomal-associated transport regulator 1, transcript variant 2 (SDCCAG3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 739, a CDR-H2 of SEQ ID NO: 1281, and a CDR-H3 of SEQ ID NO: 1823, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1010, a CDR-L2 of SEQ ID NO: 1552, and a CDR-L3 of SEQ ID NO: 2094. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 468. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SDCCAG3, mouse SDCCAG3, rat SDCCAG3, bovine SDCCAG3, or cynomolgus SDCCAG3. In some embodiments, the human SDCCAG3 comprises the sequence of SEQ ID NO: 4373.

[0331] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 832-835 for binding to SDCCAG3, wherein the antibody binds to human SDCCAG3 or murine SDCCAG3.

[0332] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Jupiter microtubule-associated homolog 2 (HN1L) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 740, a CDR-H2 of SEQ ID NO: 1282, and a CDR-H3 of SEQ ID NO: 1824, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1011, a CDR-L2 of SEQ ID NO: 1553, and a CDR-L3 of SEQ ID NO: 2095. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 469. The antibody or antigen-binding fragment thereof comprises a polypeptide consensus sequence having at least 95% sequence identity. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HN1L, mouse HN1L, rat HN1L, bovine HN1L, or cynomolgus monkey HN1L. In some embodiments, the human HN1L comprises the sequence of SEQ ID NO: 4395.

[0333] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 837 to 840 for binding to HN1L, wherein the antibody binds to human HN1L or mouse HN1L.

[0334] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to BTB domain-containing 8 (BTBD8) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 740, a CDR-H2 of SEQ ID NO: 1282, and a CDR-H3 of SEQ ID NO: 1824, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1011, a CDR-L2 of SEQ ID NO: 1553, and a CDR-L3 of SEQ ID NO: 2095. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 469. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BTBD8, mouse BTBD8, rat BTBD8, bovine BTBD8, or cynomolgus BTBD8. In some embodiments, human BTBD8 comprises the sequence of SEQ ID NO:4472.

[0335] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 842-845 for binding to BTBD8, wherein the antibody binds to human BTBD8 or mouse BTBD8.

[0336] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to neutrophil cytoplasmic factor 4, transcript variant 2 (NCF4), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, a CDR-L2 of SEQ ID NO: 1554, and a CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NCF4, mouse NCF4, rat NCF4, bovine NCF4, or cynomolgus monkey NCF4. In some embodiments, the human NCF4 comprises the sequence of SEQ ID NO: 4473.

[0337] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 847-850 for binding to NCF4, wherein the antibody binds to human NCF4 or murine NCF4.

[0338] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to t-complex 11-like 2, transcript variant X2 (TCP11L2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, a CDR-L2 of SEQ ID NO: 1554, and a CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TCP11L2, mouse TCP11L2, rat TCP11L2, bovine TCP11L2, or cynomolgus TCP11L2. In some embodiments, the human TCP11L2 comprises the sequence of SEQ ID NO: 4474.

[0339] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 852 to 855 for binding to TCP11L2, wherein the antibody binds to human TCP11L2 or murine TCP11L2.

[0340] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 741, a CDR-H2 of SEQ ID NO: 1283, and a CDR-H3 of SEQ ID NO: 1825, and / or

[0341] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C beta 2, transcript variant 4 (PLCB2) or a variant thereof, comprising at least one of a variable light chain region comprising complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1012, CDR-L2 of SEQ ID NO: 1554, and CDR-L3 of SEQ ID NO: 2096. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 470. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PLCB2, mouse PLCB2, rat PLCB2, bovine PLCB2, or cynomolgus monkey PLCB2. In some embodiments, the human PLCB2 comprises the sequence of SEQ ID NO: 4475.

[0342] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 857-860 for binding to PLCB2, wherein the antibody binds to human PLCB2 or mouse PLCB2.

[0343] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to microtubule-associated protein RP / EB family member 2, transcript variant 1 (MAPRE2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 742, a CDR-H2 of SEQ ID NO: 1284, and a CDR-H3 of SEQ ID NO: 1826, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1013, a CDR-L2 of SEQ ID NO: 1555, and a CDR-L3 of SEQ ID NO: 2097. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 471. In some embodiments, the antibody or antigen-binding fragment thereof binds to human MAPRE2, mouse MAPRE2, rat MAPRE2, bovine MAPRE2, or cynomolgus MAPRE2. In some embodiments, the human MAPRE2 comprises the sequence of SEQ ID NO: 4476.

[0344] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 862 to 865 for binding to MAPRE2, wherein the antibody binds to human MAPRE2 or mouse MAPRE2.

[0345] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 743, a CDR-H2 of SEQ ID NO: 1285, and a CDR-H3 of SEQ ID NO: 1827, and / or a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1014, a CDR of SEQ ID NO: 1556 Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD-box helicase 53 (DDX53) or a variant thereof, comprising at least one of a variable heavy chain region comprising CDR-L2, and a variable light chain region comprising CDR-L3 of SEQ ID NO: 2098. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 472. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX53, mouse DDX53, rat DDX53, bovine DDX53, or cynomolgus DDX53. In some embodiments, the human DDX53 comprises the sequence of SEQ ID NO: 4477.

[0346] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 867-870 for binding to DDX53, wherein the antibody binds to human DDX53 or murine DDX53.

[0347] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to interleukin-27 receptor subunit alpha (IL27RA) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 744, a CDR-H2 of SEQ ID NO: 1286, and a CDR-H3 of SEQ ID NO: 1828, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1015, a CDR-L2 of SEQ ID NO: 1557, and a CDR-L3 of SEQ ID NO: 2099. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 473. In some embodiments, the antibody or antigen-binding fragment thereof binds to human IL27RA, mouse IL27RA, rat IL27RA, bovine IL27RA, or cynomolgus IL27RA. In some embodiments, the human IL27RA comprises the sequence of SEQ ID NO: 4478.

[0348] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 872-875 for binding to IL27RA, wherein the antibody binds to human IL27RA or murine IL27RA.

[0349] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to deoxyhypusine synthase (DHPS) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 745, a CDR-H2 of SEQ ID NO: 1287, and a CDR-H3 of SEQ ID NO: 1829, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1016, a CDR-L2 of SEQ ID NO: 1558, and a CDR-L3 of SEQ ID NO: 2100. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 474. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DHPS, mouse DHPS, rat DHPS, bovine DHPS, or cynomolgus DHPS. In some embodiments, the human DHPS comprises the sequence of SEQ ID NO:4479.

[0350] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 877-880 for binding to DHPS, wherein the antibody binds to human DHPS or mouse DHPS.

[0351] HEAT repeat-containing transcript variants 1 (HEATR) containing at least one of the following: 3) or a variant thereof, a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 746, a CDR-H2 of SEQ ID NO: 1288, and a CDR-H3 of SEQ ID NO: 1830; and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1017, a CDR-L2 of SEQ ID NO: 1559, and a CDR-L3 of SEQ ID NO: 2101. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 475. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HEATR3, mouse HEATR3, rat HEATR3, bovine HEATR3, or cynomolgus monkey HEATR3. In some embodiments, the human HEATR3 comprises the sequence of SEQ ID NO: 4480.

[0352] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 882 to 885 for binding to HEATR3, wherein the antibody binds to human HEATR3 or mouse HEATR3.

[0353] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD-box helicase 53 (DDX53) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX53, mouse DDX53, rat DDX53, bovine DDX53, or cynomolgus DDX53. In some embodiments, the human DDX53 comprises the sequence of SEQ ID NO: 4477.

[0354] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 887-890 for binding to DDX53, wherein the antibody binds to human DDX53 or murine DDX53.

[0355] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to vezatin, an adherens junction transmembrane protein (VEZT), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds to human VEZT, mouse VEZT, rat VEZT, bovine VEZT, or cynomolgus VEZT. In some embodiments, the human VEZT comprises the sequence of SEQ ID NO: 4481.

[0356] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 892-895 for binding to VEZT, the antibody comprising human VEZT or mouse VEZT. Binds to VEZT.

[0357] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Wd repeat domain 3 (WDR3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 747, a CDR-H2 of SEQ ID NO: 1289, and a CDR-H3 of SEQ ID NO: 1831, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1018, a CDR-L2 of SEQ ID NO: 1560, and a CDR-L3 of SEQ ID NO: 2102. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 476. In some embodiments, the antibody or antigen-binding fragment thereof binds to human WDR3, mouse WDR3, rat WDR3, bovine WDR3, or cynomolgus monkey WDR3. In some embodiments, the human WDR3 comprises the sequence of SEQ ID NO: 4482.

[0358] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 897-900 for binding to WDR3, wherein the antibody binds to human WDR3 or mouse WDR3.

[0359] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DExD / H-box helicase 58 (DDX58) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 748, a CDR-H2 of SEQ ID NO: 1290, and a CDR-H3 of SEQ ID NO: 1832, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1019, a CDR-L2 of SEQ ID NO: 1561, and a CDR-L3 of SEQ ID NO: 2103. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 477. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX58, mouse DDX58, rat DDX58, bovine DDX58, or cynomolgus DDX58. In some embodiments, the human DDX58 comprises the sequence of SEQ ID NO: 4483.

[0360] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 902-905 for binding to DDX58, wherein the antibody binds to human DDX58 or murine DDX58.

[0361] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DExD / H-box helicase 58 (DDX58) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 748, a CDR-H2 of SEQ ID NO: 1290, and a CDR-H3 of SEQ ID NO: 1832, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1019, a CDR-L2 of SEQ ID NO: 1561, and a CDR-L3 of SEQ ID NO: 2103. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 477. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX58, mouse DDX58, rat DDX58, bovine DDX58, or cynomolgus DDX58. In some embodiments, the human DDX58 comprises the sequence of SEQ ID NO: 4483.

[0362] The antibody or antibody according to any one of claims 907 to 910 for binding to DDX58 Provided herein are antibodies that compete with the antigen-binding fragments, which antibodies bind to human DDX58 or murine DDX58.

[0363] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Nudix hydrolase 22, transcript variant 2 (NUDT22) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 749, a CDR-H2 of SEQ ID NO: 1291, and a CDR-H3 of SEQ ID NO: 1833, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1020, a CDR-L2 of SEQ ID NO: 1562, and a CDR-L3 of SEQ ID NO: 2104. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 478. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NUDT22, mouse NUDT22, rat NUDT22, bovine NUDT22, or cynomolgus monkey NUDT22. In some embodiments, the human NUDT22 comprises the sequence of SEQ ID NO: 4484.

[0364] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 912 to 915 for binding to NUDT22, wherein the antibody binds to human NUDT22 or mouse NUDT22.

[0365] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Jupiter microtubule-associated homolog 2 (HN1L) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 750, a CDR-H2 of SEQ ID NO: 1292, and a CDR-H3 of SEQ ID NO: 1834, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1021, a CDR-L2 of SEQ ID NO: 1563, and a CDR-L3 of SEQ ID NO: 2105. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208, The variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 479. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HN1L, mouse HN1L, rat HN1L, bovine HN1L, or cynomolgus monkey HN1L. In some embodiments, the human HN1L comprises the sequence of SEQ ID NO: 4395.

[0366] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 917-920 for binding to HN1L, wherein the antibody binds to human HN1L or mouse HN1L.

[0367] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to grancalcin, a transcript variant (GCA), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 751, a CDR-H2 of SEQ ID NO: 1293, and a CDR-H3 of SEQ ID NO: 1835, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1022, a CDR-L2 of SEQ ID NO: 1564, and a CDR-L3 of SEQ ID NO: 2106. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 480. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GCA, mouse GCA, rat GCA, bovine GCA, or cynomolgus monkey GCA. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GCA. CA comprises the sequence of SEQ ID NO:4485.

[0368] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 922-925 for binding to GCA, wherein the antibody binds to human GCA or murine GCA.

[0369] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to endoplasmic reticulum protein 27, transcript variant 1 (ERP27) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 752, a CDR-H2 of SEQ ID NO: 1294, and a CDR-H3 of SEQ ID NO: 1836, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1023, a CDR-L2 of SEQ ID NO: 1565, and a CDR-L3 of SEQ ID NO: 2107. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 481. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ERP27, mouse ERP27, rat ERP27, bovine ERP27, or cynomolgus ERP27. In some embodiments, the human ERP27 comprises the sequence of SEQ ID NO: 4469.

[0370] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 927-930 for binding to ERP27, wherein the antibody binds to human ERP27 or murine ERP27.

[0371] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to RNA polymerase III subunit g (POLR3G) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 753, a CDR-H2 of SEQ ID NO: 1295, and a CDR-H3 of SEQ ID NO: 1837, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1024, a CDR-L2 of SEQ ID NO: 1566, and a CDR-L3 of SEQ ID NO: 2108. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 482. In some embodiments, the antibody or antigen-binding fragment thereof binds to human POLR3G, mouse POLR3G, rat POLR3G, bovine POLR3G, or cynomolgus POLR3G. In some embodiments, the human POLR3G comprises the sequence of SEQ ID NO: 4486.

[0372] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 932-935 for binding to POLR3G, wherein the antibody binds to human POLR3G or mouse POLR3G.

[0373] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to sorting nexin 1, transcript variant 1 (SNX1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 754, a CDR-H2 of SEQ ID NO: 1296, and a CDR-H3 of SEQ ID NO: 1838, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1025, a CDR-L2 of SEQ ID NO: 1567, and a CDR-L3 of SEQ ID NO: 2109. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 483. In some embodiments, the antibody or antigen-binding fragment thereof binds to human SNX1, mouse SNX1, rat SNX1, bovine SNX1, or cynomolgus monkey SNX1. In some embodiments, the human SNX1 comprises the sequence of SEQ ID NO: 4487.

[0374] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 937-940 for binding to SNX1, wherein the antibody binds to human SNX1 or mouse SNX1.

[0375] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to SAA2-SAA3 (AB937783.1_frag) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 755, a CDR-H2 of SEQ ID NO: 1297, and a CDR-H3 of SEQ ID NO: 1839, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1026, a CDR-L2 of SEQ ID NO: 1568, and a CDR-L3 of SEQ ID NO: 2110. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 484. In some embodiments, the antibody or antigen-binding fragment thereof binds to human AB937783.1_frag, mouse AB937783.1_frag, rat AB937783.1_frag, bovine AB937783.1_frag, or cynomolgus monkey AB937783.1_frag. In some embodiments, human AB937783.1_frag comprises the sequence of SEQ ID NO:4488.

[0376] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 942-945 for binding to AB937783.1_frag, wherein the antibody binds to human AB937783.1_frag or murine AB937783.1_frag.

[0377] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to proteasome 26S subunit, non-ATPase 3 (PSMD3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 755, a CDR-H2 of SEQ ID NO: 1297, and a CDR-H3 of SEQ ID NO: 1839, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1026, a CDR-L2 of SEQ ID NO: 1568, and a CDR-L3 of SEQ ID NO: 2110. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 484. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PSMD3, mouse PSMD3, rat PSMD3, bovine PSMD3, or cynomolgus PSMD3. In some embodiments, the human PSMD3 comprises the sequence of SEQ ID NO: 4489.

[0378] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 947-950 for binding to PSMD3, wherein the antibody binds to human PSMD3 or mouse PSMD3.

[0379] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 756, a CDR-H2 of SEQ ID NO: 1298, and a CDR-H3 of SEQ ID NO: 1840, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1027, a CDR-L2 of SEQ ID NO: 1569, and a CDR-L3 of SEQ ID NO: 2111; Provided herein are antibodies or antigen-binding fragments thereof that selectively bind to CRK-like proto-oncogene, adaptor protein, transcript variant 1 (CRKL) or variants thereof, including one of: In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 485. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CRKL, mouse CRKL, rat CRKL, bovine CRKL, or cynomolgus monkey CRKL. In some embodiments, the human CRKL comprises the sequence of SEQ ID NO: 4490.

[0380] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 952-955 for binding to CRKL, wherein the antibody binds to human CRKL or murine CRKL.

[0381] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to F-box protein 2 (FBXO2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 757, a CDR-H2 of SEQ ID NO: 1299, and a CDR-H3 of SEQ ID NO: 1841, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1028, a CDR-L2 of SEQ ID NO: 1570, and a CDR-L3 of SEQ ID NO: 2112. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 486. In some embodiments, the antibody or antigen-binding fragment thereof binds to human FBXO2, mouse FBXO2, rat FBXO2, bovine FBXO2, or cynomolgus monkey FBXO2. In some embodiments, the human FBXO2 comprises the sequence of SEQ ID NO: 4491.

[0382] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 957-960 for binding to FBXO2, wherein the antibody binds to human FBXO2 or mouse FBXO2.

[0383] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to tubulin gamma 1 (TUBG1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 757, a CDR-H2 of SEQ ID NO: 1299, and a CDR-H3 of SEQ ID NO: 1841, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1028, a CDR-L2 of SEQ ID NO: 1570, and a CDR-L3 of SEQ ID NO: 2112. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 486. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TUBG1, mouse TUBG1, rat TUBG1, bovine TUBG1, or cynomolgus monkey TUBG1. In some embodiments, the human TUBG1 comprises the sequence of SEQ ID NO: 4492.

[0384] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 962-965 for binding to TUBG1, wherein the antibody binds to human TUBG1 or murine TUBG1.

[0385] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 759, a CDR-H2 of SEQ ID NO: 1301, and a CDR-H3 of SEQ ID NO: 1843, and / or Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to oxidation-resistant 1, transcript variant 1 (OXR1) or a variant thereof, comprising at least one of a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1030, a CDR-L2 of SEQ ID NO: 1572, and a CDR-L3 of SEQ ID NO: 2114. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 488. In some embodiments, the antibody or antigen-binding fragment thereof binds to human OXR1, mouse OXR1, rat OXR1, bovine OXR1, or cynomolgus OXR1. In some embodiments, the human OXR1 comprises the sequence of SEQ ID NO: 4493.

[0386] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 967-970 for binding to OXR1, wherein the antibody binds to human OXR1 or mouse OXR1.

[0387] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to ankyrin repeat domain 20 family member a5 (ANKRD20A5P) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds to human ANKRD20A5P, mouse ANKRD20A5P, rat ANKRD20A5P, bovine ANKRD20A5P, or cynomolgus monkey ANKRD20A5P. In some embodiments, the human ANKRD20A5P comprises the sequence of SEQ ID NO: 4494.

[0388] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 972 to 975 for binding to ANKRD20A5P, wherein the antibody binds to human ANKRD20A5P or murine ANKRD20A5P.

[0389] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kirre-like nephrin family adhesion molecule 1 (KIRREL) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KIRREL, mouse KIRREL, rat KIRREL, bovine KIRREL, or cynomolgus KIRREL. In some embodiments, human KIRREL comprises the sequence of SEQ ID NO: 4495.

[0390] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 977-980 for binding to KIRREL, wherein the antibody binds to human KIRREL or murine KIRREL.

[0391] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to GRB10-interacting GYF protein 1, transcript variant X10 (GIGYF1), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 760, a CDR-H2 of SEQ ID NO: 1302, and a CDR-H3 of SEQ ID NO: 1844, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1031, a CDR-L2 of SEQ ID NO: 1573, and a CDR-L3 of SEQ ID NO: 2115. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 489. In some embodiments, the antibody or antigen-binding fragment thereof binds to human GIGYF1, mouse GIGYF1, rat GIGYF1, bovine GIGYF1, or cynomolgus GIGYF1. In some embodiments, the human GIGYF1 comprises the sequence of SEQ ID NO: 4496.

[0392] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 982 to 985 for binding to GIGYF1, wherein the antibody binds to human GIGYF1 or mouse GIGYF1.

[0393] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to defensin alpha 3 (DEFA3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 761, a CDR-H2 of SEQ ID NO: 1303, and a CDR-H3 of SEQ ID NO: 1845, and a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1032, a CDR-L2 of SEQ ID NO: 1574, and a CDR-L3 of SEQ ID NO: 2116. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 490. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DEFA3, mouse DEFA3, rat DEFA3, bovine DEFA3, or cynomolgus DEFA3. In some embodiments, the human DEFA3 comprises the sequence of SEQ ID NO:4497.

[0394] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 987-990 for binding to DEFA3, wherein the antibody binds to human DEFA3 or murine DEFA3.

[0395] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to radial spoke head 14 homolog (RSPH14) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 762, a CDR-H2 of SEQ ID NO: 1304, and a CDR-H3 of SEQ ID NO: 1846, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1033, a CDR-L2 of SEQ ID NO: 1575, and a CDR-L3 of SEQ ID NO: 2117. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 491. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RSPH14, mouse RSPH14, rat RSPH14, bovine RSPH14, or cynomolgus RSPH14. In some embodiments, the human RSPH14 comprises the sequence of SEQ ID NO: 4498.

[0396] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 992 to 995 for binding to RSPH14, wherein the antibody binds to human RSPH14 or murine RSPH14.

[0397] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to CC motif chemokine ligand 2 (CCL2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 763, a CDR-H2 of SEQ ID NO: 1305, and a CDR-H3 of SEQ ID NO: 1847, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1034, a CDR-L2 of SEQ ID NO: 1576, and a CDR-L3 of SEQ ID NO: 2118. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 492. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CCL2, mouse CCL2, rat CCL2, bovine CCL2, or cynomolgus CCL2. In some embodiments, the human CCL2 comprises the sequence of SEQ ID NO:4499.

[0398] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 997-1000 for binding to CCL2, wherein the antibody binds to human CCL2 or murine CCL2.

[0399] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to killer cell lectin-like receptor C1, transcript variant 3 (KLRC1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 764, a CDR-H2 of SEQ ID NO: 1306, and a CDR-H3 of SEQ ID NO: 1848, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1035, a CDR-L2 of SEQ ID NO: 1577, and a CDR-L3 of SEQ ID NO: 2119. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 493. In some embodiments, the antibody or antigen-binding fragment thereof binds to human KLRCl, mouse KLRCl, rat KLRCl, bovine KLRCl, or cynomolgus monkey KLRCl. In some embodiments, the human KLRCl comprises the sequence of SEQ ID NO: 4500.

[0400] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1002 to 1005 for binding to KLRC1, wherein the antibody binds to human KLRC1 or mouse KLRC1.

[0401] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to Kelch-like family member 12, transcript variant 2 (KLHL12), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 764, a CDR-H2 of SEQ ID NO: 1306, and a CDR-H3 of SEQ ID NO: 1848, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1035, a CDR-L2 of SEQ ID NO: 1577, and a CDR-L3 of SEQ ID NO: 2119. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 493. In some embodiments, the antibody or antigen-binding fragment thereof is human KLHL12, mouse KLHL12, rat KLHL12, bovine KLHL12, or cynomolgus monkey. In some embodiments, human KLHL12 comprises the sequence of SEQ ID NO: 4501.

[0402] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1007 to 1010 for binding to KLHL12, wherein the antibody binds to human KLHL12 or mouse KLHL12.

[0403] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to neural retina leucine zipper, transcript variant X4 (NRL), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 765, a CDR-H2 of SEQ ID NO: 1307, and a CDR-H3 of SEQ ID NO: 1849, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1036, a CDR-L2 of SEQ ID NO: 1578, and a CDR-L3 of SEQ ID NO: 2120. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 223, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 494. In some embodiments, the antibody or antigen-binding fragment thereof binds to human NRL, mouse NRL, rat NRL, bovine NRL, or cynomolgus monkey NRL. In some embodiments, the human NRL comprises the sequence of SEQ ID NO:4502.

[0404] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1012 to 1015 for binding to NRL, wherein the antibody binds to human NRL or murine NRL.

[0405] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to phospholipase C delta 4 (PLCD4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 766, a CDR-H2 of SEQ ID NO: 1308, and a CDR-H3 of SEQ ID NO: 1850, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1037, a CDR-L2 of SEQ ID NO: 1579, and a CDR-L3 of SEQ ID NO: 2121. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 495. In some embodiments, the antibody or antigen-binding fragment thereof binds to human PLCD4, mouse PLCD4, rat PLCD4, bovine PLCD4, or cynomolgus PLCD4. In some embodiments, the human PLCD4 comprises the sequence of SEQ ID NO:4503.

[0406] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1017-1020 for binding to PLCD4, wherein the antibody binds to human PLCD4 or mouse PLCD4.

[0407] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to coiled-coil domain-containing 74B, transcript variant 2 (CCDC74B), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 767, a CDR-H2 of SEQ ID NO: 1309, and a CDR-H3 of SEQ ID NO: 1851, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1038, a CDR-L2 of SEQ ID NO: 1580, and a CDR-L3 of SEQ ID NO: 2122. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 496. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CCDC74B, mouse CCDC74B, rat CCDC74B, bovine CCDC74B, or cynomolgus CCDC74B. In some embodiments, the human CCDC74B comprises the sequence of SEQ ID NO: 4504.

[0408] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1022-1025 for binding to CCDC74B, wherein the antibody binds to human CCDC74B or murine CCDC74B.

[0409] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DEAD-box helicase 53 (DDX53) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 768, a CDR-H2 of SEQ ID NO: 1310, and a CDR-H3 of SEQ ID NO: 1852, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1039, a CDR-L2 of SEQ ID NO: 1581, and a CDR-L3 of SEQ ID NO: 2123. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 226, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 497. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DDX53, mouse DDX53, rat DDX53, bovine DDX53, or cynomolgus DDX53. In some embodiments, the human DDX53 comprises the sequence of SEQ ID NO: 4477.

[0410] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1027-1030 for binding to DDX53, wherein the antibody binds to human DDX53 or mouse DDX53.

[0411] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to HSPA (Hsp70) binding protein 1, transcript variant 2 (HSPBP1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 769, a CDR-H2 of SEQ ID NO: 1311, and a CDR-H3 of SEQ ID NO: 1853, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1040, a CDR-L2 of SEQ ID NO: 1582, and a CDR-L3 of SEQ ID NO: 2124. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 498. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HSPBP1, mouse HSPBP1, rat HSPBP1, bovine HSPBP1, or cynomolgus HSPBP1. In some embodiments, the human HSPBP1 comprises the sequence of SEQ ID NO: 4505.

[0412] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1032 to 1035 for binding to HSPBP1, wherein the antibody binds to human HSPBP1 or mouse HSPBP1.

[0413] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to heat shock protein family A (Hsp70) member 2 (HSPA2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 769, a CDR-H2 of SEQ ID NO: 1311, and a CDR-H3 of SEQ ID NO: 1853, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1040, a CDR-L2 of SEQ ID NO: 1582, and a CDR-L3 of SEQ ID NO: 2124. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 498. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HSPA2, mouse HSPA2, rat HSPA2, bovine HSPA2, or cynomolgus HSPA2. In some embodiments, the human HSPA2 comprises the sequence of SEQ ID NO: 4506.

[0414] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1037 to 1040 for binding to HSPA2, wherein the antibody binds to human HSPA2 or murine HSPA2.

[0415] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to BCL2-associated athanogene 2 (BAG2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 769, a CDR-H2 of SEQ ID NO: 1311, and a CDR-H3 of SEQ ID NO: 1853, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1040, a CDR-L2 of SEQ ID NO: 1582, and a CDR-L3 of SEQ ID NO: 2124. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 498. In some embodiments, the antibody or antigen-binding fragment thereof binds to human BAG2, mouse BAG2, rat BAG2, bovine BAG2, or cynomolgus BAG2. In some embodiments, the human BAG2 comprises the sequence of SEQ ID NO: 4507.

[0416] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1042 to 1045 for binding to BAG2, wherein the antibody binds to human BAG2 or murine BAG2.

[0417] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to C-X-C motif chemokine receptor 4, transcript variant 2 (CXCR4) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 770, a CDR-H2 of SEQ ID NO: 1312, and a CDR-H3 of SEQ ID NO: 1854, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1041, a CDR-L2 of SEQ ID NO: 1583, and a CDR-L3 of SEQ ID NO: 2125. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 499. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CXCR4, mouse CXCR4, rat CXCR4, bovine CXCR4, or cynomolgus CXCR4. In some embodiments, the human CXCR4 comprises the sequence of SEQ ID NO: 4508.

[0418] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1047-1050 for binding to CXCR4, wherein the antibody binds to human CXCR4 or murine CXCR4.

[0419] a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 770, a CDR-H2 of SEQ ID NO: 1312, and a CDR-H3 of SEQ ID NO: 1854, and / or a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1041, a CDR of SEQ ID NO: 1583 Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to long intergenic non-protein-coding RNA 242 (LINC00242) or a variant thereof, comprising at least one of a variable heavy chain region comprising CDR-L2, and a variable light chain region comprising CDR-L3 of SEQ ID NO: 2125. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 499. In some embodiments, the antibody or antigen-binding fragment thereof binds to human LINC00242, mouse LINC00242, rat LINC00242, bovine LINC00242, or cynomolgus monkey LINC00242. In some embodiments, human LINC00242 comprises the sequence of SEQ ID NO: 4509.

[0420] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1052-1055 for binding to LINC00242, wherein the antibody binds to human LINC00242 or murine LINC00242.

[0421] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to signal transducer and activator of transcription 5A, transcription variant 2 (STAT5A), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 771, a CDR-H2 of SEQ ID NO: 1313, and a CDR-H3 of SEQ ID NO: 1855, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1042, a CDR-L2 of SEQ ID NO: 1584, and a CDR-L3 of SEQ ID NO: 2126. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 500. In some embodiments, the antibody or antigen-binding fragment thereof binds to human STAT5A, mouse STAT5A, rat STAT5A, bovine STAT5A, or cynomolgus STAT5A. In some embodiments, the human STAT5A comprises the sequence of SEQ ID NO: 4510.

[0422] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1057-1060 for binding to STAT5A, wherein the antibody binds to human STAT5A or mouse STAT5A.

[0423] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to quinoid dihydropteridine reductase, transcript variant 1 (QDPR), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 771, a CDR-H2 of SEQ ID NO: 1313, and a CDR-H3 of SEQ ID NO: 1855, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1042, a CDR-L2 of SEQ ID NO: 1584, and a CDR-L3 of SEQ ID NO: 2126. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 500. In some embodiments, the antibody or antigen-binding fragment thereof binds to human QDPR, mouse QDPR, rat QDPR, bovine QDPR, or cynomolgus QDPR. In some embodiments, the human QDPR comprises the sequence of SEQ ID NO: 4438.

[0424] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1062-1065 for binding to QDPR, wherein the antibody binds to human QDPR or mouse QDPR.

[0425] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to calcium and integrin binding 1, transcript variant b (CIB1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 773, a CDR-H2 of SEQ ID NO: 1315, and a CDR-H3 of SEQ ID NO: 1857, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1044, a CDR-L2 of SEQ ID NO: 1586, and a CDR-L3 of SEQ ID NO: 2128. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 502. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CIB1, mouse CIB1, rat CIB1, bovine CIB1, or cynomolgus monkey CIB1. In some embodiments, the human CIB1 comprises the sequence of SEQ ID NO: 4511.

[0426] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1067-1070 for binding to CIB1, wherein the antibody binds to human CIB1 or murine CIB1.

[0427] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to t-SNARE domain-containing 1, transcript variant 1 (TSNARE1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 773, a CDR-H2 of SEQ ID NO: 1315, and a CDR-H3 of SEQ ID NO: 1857, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1044, a CDR-L2 of SEQ ID NO: 1586, and a CDR-L3 of SEQ ID NO: 2128. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 502. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TSNARE1, mouse TSNARE1, rat TSNARE1, bovine TSNARE1, or cynomolgus TSNARE1. In some embodiments, the human TSNARE1 comprises the sequence of SEQ ID NO: 4512.

[0428] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1072 to 1075 for binding to TSNARE1, wherein the antibody binds to human TSNARE1 or mouse TSNARE1.

[0429] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to HAUS augmin-like complex subunit 1, transcript variant 1 (HAUS1), or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 774, a CDR-H2 of SEQ ID NO: 1316, and a CDR-H3 of SEQ ID NO: 1858, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1045, a CDR-L2 of SEQ ID NO: 1587, and a CDR-L3 of SEQ ID NO: 2129. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 503. In some embodiments, the antibody or antigen-binding fragment thereof binds to human HAUS1, mouse HAUS1, rat HAUS1, bovine HAUS1, or cynomolgus monkey HAUS1. In some embodiments, the human HAUS1 comprises the sequence of SEQ ID NO: 4513.

[0430] The antibody or antibody according to any one of claims 1077 to 1080, which binds to HAUS1 Provided herein are antibodies that compete with the antibody or antigen-binding fragment thereof, which bind to human HAUS1 or mouse HAUS1.

[0431] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to DPY30 domain-containing 1, transcript variant X4 (DYDC1) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 774, a CDR-H2 of SEQ ID NO: 1316, and a CDR-H3 of SEQ ID NO: 1858, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1045, a CDR-L2 of SEQ ID NO: 1587, and a CDR-L3 of SEQ ID NO: 2129. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 503. In some embodiments, the antibody or antigen-binding fragment thereof binds to human DYDC1, mouse DYDC1, rat DYDC1, bovine DYDC1, or cynomolgus DYDC1. In some embodiments, the human DYDC1 comprises the sequence of SEQ ID NO: 4514.

[0432] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1082 to 1085 for binding to DYDC1, wherein the antibody binds to human DYDC1 or mouse DYDC1.

[0433] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to transforming growth factor beta 3 (TGFB3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 775, a CDR-H2 of SEQ ID NO: 1317, and a CDR-H3 of SEQ ID NO: 1859, and a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1046, a CDR-L2 of SEQ ID NO: 1588, and a CDR-L3 of SEQ ID NO: 2130. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 504. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TGFB3, mouse TGFB3, rat TGFB3, bovine TGFB3, or cynomolgus TGFB3. In some embodiments, the human TGFB3 comprises the sequence of SEQ ID NO:4515.

[0434] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1087-1090 for binding to TGFB3, wherein the antibody binds to human TGFB3 or mouse TGFB3.

[0435] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to chymotrypsinogen B2 (CTRB2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 776, a CDR-H2 of SEQ ID NO: 1318, and a CDR-H3 of SEQ ID NO: 1860, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1047, a CDR-L2 of SEQ ID NO: 1589, and a CDR-L3 of SEQ ID NO: 2131. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 505. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CTRB2, mouse CTRB2, rat CTRB2, bovine CTRB2, or cynomolgus CTRB2. In some embodiments, the human CTRB2 comprises the sequence of SEQ ID NO: 4516.

[0436] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1092 to 1095 for binding to CTRB2, wherein the antibody binds to human or mouse CTRB2. Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to NFKB inhibitor beta, transcript variant 1 (NFKBIB) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 777, a CDR-H2 of SEQ ID NO: 1319, and a CDR-H3 of SEQ ID NO: 1861, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1048, a CDR-L2 of SEQ ID NO: 1590, and a CDR-L3 of SEQ ID NO: 2132. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 506.

[0437] In some embodiments, the antibody or antigen-binding fragment thereof binds to human NFKBIB, mouse NFKBIB, rat NFKBIB, bovine NFKBIB, or cynomolgus NFKBIB. In some embodiments, the human NFKBIB comprises the sequence of SEQ ID NO: 4517.

[0438] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1097-1100 for binding to NFKBIB, wherein the antibody binds to human NFKBIB or mouse NFKBIB.

[0439] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to cyclin-dependent kinase 2-associated protein 2, transcript variant 1 (CDK2AP2) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 777, a CDR-H2 of SEQ ID NO: 1319, and a CDR-H3 of SEQ ID NO: 1861, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1048, a CDR-L2 of SEQ ID NO: 1590, and a CDR-L3 of SEQ ID NO: 2132. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 506. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CDK2AP2, mouse CDK2AP2, rat CDK2AP2, bovine CDK2AP2, or cynomolgus CDK2AP2. In some embodiments, the human CDK2AP2 comprises the sequence of SEQ ID NO: 4518.

[0440] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1102 to 1105 for binding to CDK2AP2, wherein the antibody binds to human CDK2AP2 or mouse CDK2AP2.

[0441] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to lipase family member N, transcript variant X1 (LIPN) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 778, a CDR-H2 of SEQ ID NO: 1320, and a CDR-H3 of SEQ ID NO: 1862, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1049, a CDR-L2 of SEQ ID NO: 1591, and a CDR-L3 of SEQ ID NO: 2133. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 507. In some embodiments, the antibody or antigen-binding fragment thereof selectively binds to human LIPN, mouse LIPN, or a variant thereof. In some embodiments, the human LIPN comprises the sequence of SEQ ID NO: 4519.

[0442] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1107-1110 for binding to LIPN, wherein the antibody binds to human LIPN or mouse LIPN.

[0443] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to G protein signaling 14, transcript variant 1 (RGS14) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 779, a CDR-H2 of SEQ ID NO: 1321, and a CDR-H3 of SEQ ID NO: 1863, and / or a variable light chain region comprising a complementarity determining region light chain 1 (CDR-L1) of SEQ ID NO: 1050, a CDR-L2 of SEQ ID NO: 1592, and a CDR-L3 of SEQ ID NO: 2134. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 508. In some embodiments, the antibody or antigen-binding fragment thereof binds to human RGS 14, mouse RGS 14, rat RGS 14, bovine RGS 14, or cynomolgus monkey RGS 14. In some embodiments, the human RGS 14 comprises the sequence of SEQ ID NO: 4520.

[0444] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1112-1115 for binding to RGS14, wherein the antibody binds to human RGS14 or murine RGS14.

[0445] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to leucine-rich repeat-containing 14, transcript variant 1 (LRRC14) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 779, a CDR-H2 of SEQ ID NO: 1321, and a CDR-H3 of SEQ ID NO: 1863, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1050, a CDR-L2 of SEQ ID NO: 1592, and a CDR-L3 of SEQ ID NO: 2134. In some embodiments, the variable heavy chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237, and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 508. In some embodiments, the antibody or antigen-binding fragment thereof binds to human LRRC14, mouse LRRC14, rat LRRC14, bovine LRRC14, or cynomolgus monkey LRRC14. In some embodiments, the human LRRC14 comprises the sequence of SEQ ID NO: 4521.

[0446] Provided herein is an antibody that competes with the antibody or antigen-binding fragment of any one of claims 1117 to 1120 for binding to LRRC14, wherein the antibody binds to human LRRC14 or mouse LRRC14.

[0447] Provided herein is an antibody or antigen-binding fragment thereof that selectively binds to transforming growth factor beta-induced (TGFB3) or a variant thereof, comprising at least one of a variable heavy chain region comprising a complementarity-determining region heavy chain 1 (CDR-H1) of SEQ ID NO: 780, a CDR-H2 of SEQ ID NO: 1322, and a CDR-H3 of SEQ ID NO: 1864, and / or a variable light chain region comprising a complementarity-determining region light chain 1 (CDR-L1) of SEQ ID NO: 1051, a CDR-L2 of SEQ ID NO: 1593, and a CDR-L3 of SEQ ID NO: 2135. In some embodiments, the variable heavy chain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238. and the variable light chain comprises a polypeptide consensus sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 509. In some embodiments, the antibody or antigen-binding fragment thereof binds to human TGFBI, mouse TGFBI, rat TGFBI, bovine TGFBI, or cynomolgus TGFBI. In some...

Claims

[Claim 1] The invention described in this specification.

Images